Document:

Stock Subscription and Registration Rights Agreement

 Exhibit 10.29 
 STOCK SUBSCRIPTION AND REGISTRATION RIGHTS AGREEMENT 
 This STOCK SUBSCRIPTION AND REGISTRATION
RIGHTS AGREEMENT (this “Agreement”), dated as of August 18, 2008, is made by and among Peplin, Inc., a Delaware corporation, with headquarters located at 6475 Christie Avenue, Emeryville, California 94608 (the
“Company”), and the several investors listed on Exhibit A hereto (each an “Investor,” and collectively, the “Investors”). 
 RECITALS 
 A.     The Company and the Investors are
executing and delivering this Agreement in reliance upon the exemptions from securities registration afforded by Regulation S and Regulation D, as applicable, of the Securities Act of 1933, as amended (the “Securities Act”); and

 B.     The Investors desire to purchase, and the Company wishes to sell, upon the terms and conditions stated in this
Agreement (i) an aggregate of 3,980,259 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), for the purchase price as set forth on Exhibit A hereto
and (ii) warrants, in the form attached hereto as Exhibit B-1 with respect to Investors that are “non-U.S. Persons” within the meaning of Rule 902 of Regulation S, and in the form attached hereto as Exhibit B-2 with
respect to all other Investors (collectively, the “Warrants”) to purchase up to an aggregate of 1,326,753 shares of Common Stock. Solely for descriptive purposes as set forth herein, the Shares and Warrants may be denominated as
“Units,” with each Unit consisting of three Shares and a Warrant exercisable for one share of Common Stock. Subject to the transfer restrictions set forth herein, the Shares and the Warrants will be immediately separable upon
issuance. The shares of Common Stock issuable upon exercise of the Warrants shall be referred to herein as the “Warrant Shares.” The Shares, the Warrants and the Warrant Shares shall collectively be referred to herein as the
“Securities.” 
 C.     Subject to the terms and conditions set forth herein, 1,326,753 Units will be
issued and sold to the Investors on the Closing Date (as defined below) for a per Unit purchase price equal to $18.14, or approximately $24,067,299 in the aggregate, with each Investor purchasing the number of Units set forth opposite such
Investor’s name on Exhibit A. 
 AGREEMENT 
 NOW THEREFORE, in consideration of the premises and the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and the
Investors hereby agree as follows: 
 ARTICLE I 
 DEFINITIONS 
 1.1     Definitions. In addition to the terms defined
elsewhere in this Agreement, the following terms used in this Agreement shall be construed to have the meanings set forth below: 
 (a)     “ASIC” means the Australian Securities and Investments Commission. 
 (b)     “ASX” means the ASX Limited (ACN 008 624 691). 

 (c)     “Business Day” means any day except Saturday, Sunday and any
day that is a federal legal holiday or a day on which banking institutions in the State of New York and in Brisbane, Australia are authorized or required by law or other governmental action to close. 
 (d)     “CDI” means a CHESS Depositary Interests representing an interest in a Share or a Warrant Share, as the case
may be. 
 (e)     “Commission” means the United States Securities and Exchange Commission. 

(f)     “Company Counsel” means Latham & Watkins LLP, counsel to the Company. 
 (g)     “Corporations Act” means the Australian Corporations Act (2001) (Cth). 
 (h)     “Distribution Compliance Period” shall have the meaning set forth in Rules 902(f) and 903(b)(3)(iii) of
Regulation S. 
 (i)     “dollars” or “$” shall mean United States dollars. 

(j)     “Exchange Act” means the Securities Exchange Act of 1934, as amended. 
 (k)     “Holder” means any Investor or any transferee or assignee thereof to whom an Investor assigns its rights
under this Agreement and who agrees to become bound by the provisions of this Agreement in accordance with Article IX hereof and any transferee or assignee thereof to whom a transferee or assignee assigns its rights under this Agreement and
who agrees to become bound by the provisions of this Agreement in accordance with Article IX hereof. 
 (l)    
“Listing Rules” means the ASX Listing Rules. 
 (m)     “Person” means an individual or
corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind. 
 (n)     “Proceeding” means an action, claim, suit, investigation or proceeding (including, without limitation, an
investigation or partial proceeding, such as a deposition), whether commenced or threatened in writing. 
 (o)    
“Registrable Securities” means all of the Shares and Warrant Shares sold pursuant to this Agreement, together with any shares of Common Stock issued or issuable upon any stock split, dividend or other distribution, recapitalization,
share exchange or similar event with respect to the foregoing. 
 (p)     “register,”
“registered” and “registration” refer to a registration effected by preparing and filing one or more Registration Statements (as defined above) in compliance with the Securities Act and pursuant to Rule 415 of the
Securities Act and the declaration or ordering of effectiveness of such Registration Statement(s) by the Commission. 
 (q)     “Commission Guidance” means (i) any publicly-available guidance, comment, press release or rule of general applicability of the Commission staff or (ii) written 

 
comments, requirements or requests of the Commission staff to the Company in connection with the review of a Registration Statement or otherwise. 

(r)     “Short Sales” means, without limitation, all “short sales” as defined in Rule 3b-3 of the
Exchange Act. 
 (s)     “Stockholders” means the holders of the Company’s securities as of the
date hereof. 
 (t)     “Stockholder Approval” means the approval of the majority of the Stockholders
for the issuance of the Units as contemplated herein, as required by the Listing Rules. 
 (u)    
“Subsidiary” means any “significant subsidiary” as defined in Rule 1-02(w) of the Regulation S-X promulgated by the Commission under the Exchange Act. 
 (v)     “U.S. Person” shall have the meaning set forth in Rule 902(k) of Regulation S. 
 ARTICLE II 
 PURCHASE AND SALE OF
UNITS 
 2.1     Closing. Payment for the Units shall
be made to the Company by each Investor in immediately available funds against delivery of such Units for the respective accounts of the several Investors at 11:00 a.m., New York City time, not later than the fourteenth (14th) Business Day following the Company obtaining the Stockholder Approval (the “Closing”). The time and date of such payment are
hereinafter referred to as the “Closing Date.” Subject to the terms and conditions set forth in this Agreement, at the Closing, the Company will issue and sell to each Investor, and each Investor will purchase from the Company,
severally and not jointly, the number of Units set forth opposite the name of such Investor on Exhibit A hereto for such aggregate dollar amount as set forth opposite each Investor’s name on Exhibit A hereto (each such amount
being the “Purchase Price”). The Closing shall take place at the offices of Company Counsel, at 650 Town Center Drive, 20th Floor, Costa Mesa, California 92626, or at such other location and on such other date as the Company and the
Investors purchasing a majority of the Units to be purchased pursuant to this Agreement shall mutually agree (provided that written notice of any change to those details is given to all Investors). 
 2.2     Closing Deliveries. 
 (a)     At the Closing, the Company shall: (i) issue, or cause to be issued, book-entry Shares (or certificated Shares, if so requested by such Investor) in the name of such Investor,
registered to the account of such Investor, on the records of the Company’s transfer agent for its Common Stock in such amounts as set forth opposite such Investor’s name on Exhibit A hereto and (ii) issue such number of
Warrants being acquired by such Investor as set forth on Exhibit A hereto, subject to Section 8.3(b). 
 (b)     At the Closing, each Investor shall deliver or cause to be delivered to the Company such Investor’s respective Purchase Price in accordance with Section 2.1. 

 2.3     Pre-Closing Obligations. The Company agrees that, between the date
hereof and the Closing Date, it shall carry on its business in the usual, regular and ordinary course, consistent with past practice. Without limiting the foregoing, and as an extension thereof, between the date of this Agreement and the Closing
Date, the Company shall not (except with the prior written consent of the Investors purchasing a majority of the Units to be purchased pursuant to this Agreement, which consent shall not be unreasonably withheld): 
 (a)     enter into, amend or terminate, any material contract to which the Company is a party, or enter into (or make any binding
commitment to enter into) any other obligation which could reasonably be expected to have a Material Adverse Effect (as defined herein) on the Company; 
 (b)     sell any shares of Common Stock, or securities convertible into shares of Common Stock, at a per share purchase price less than $7.00 per share of Common Stock; 
 (c)     increase, reduce or otherwise alter its share capital or grant any options for the issue of Common Stock or other securities
of the Company, other than pursuant to the Company’s 2007 Incentive Award Plan and the issuance of Common Stock in connection with the acquisition of Neosil, Inc., on the terms announced by the Company on June 10, 2008; or 
 (d)     declare or pay a dividend on its Common Stock or any other securities of the Company. 
 ARTICLE III 
 REPRESENTATIONS AND
WARRANTIES OF THE COMPANY 
 The Company hereby represents and warrants to each of the Investors that as at the date of this Agreement
and as of the Closing Date that: 
 3.1     Organization and Qualification. The Company and each of its
Subsidiaries is an entity duly incorporated or otherwise organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization, as applicable, with the requisite power and authority to own, lease
and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any of its Subsidiaries is in violation of any of the provisions of its respective certificate or articles of incorporation, by-laws or
other organizational or charter documents. The Company and each of its Subsidiaries is duly qualified to conduct business and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business
conducted or property owned or leased by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, would not, individually or in the aggregate, have (i) a material and adverse
effect on the legality, validity or enforceability of this Agreement, (ii) a material and adverse effect on the results of operations, assets, capitalization, business or condition (financial or otherwise) of the Company and its Subsidiaries,
taken as a whole, or (iii) a material adverse impairment to the Company’s ability to perform on a timely basis its obligations under this Agreement and the transactions contemplated hereby (as used in this Agreement, any of (i),
(ii) or (iii), shall be referred to as a “Material Adverse Effect”). 
 3.2     Authorization;
Enforcement. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated hereby and otherwise to carry out its obligations hereunder. The execution and delivery of this Agreement by
the Company 

 
and the consummation by it of the transactions contemplated hereby have been duly authorized by all necessary action on the part of the Company, its officers
and directors and no further action is required by such parties in connection therewith other than the filings referred to in Section 3.6 hereof and obtaining the Stockholder Approval. This Agreement and the Warrants have been duly
executed by the Company and, when delivered in accordance with the terms hereof and thereof, will constitute the valid and binding obligation of the Company enforceable against the Company in accordance with their terms. 
 3.3     No Violations. The Company is not (i) in violation of its charter, bylaws, or other organizational document;
(ii) in violation of any applicable law, administrative regulation, ordinance or order of any court or governmental agency, arbitration panel or authority applicable to the Company, which violation, individually or in the aggregate, would be
reasonably likely to have a Material Adverse Effect; or (iii) in default (and there exists no condition which, with the passage of time or otherwise, would constitute a default) in the performance of any bond, debenture, note or any other
evidence of indebtedness in any indenture, mortgage, deed of trust or any other agreement or instrument to which the Company is a party or by which the Company is bound or by which the properties of the Company are bound, which would be reasonably
likely to have a Material Adverse Effect. 
 3.4     Governmental Permits, Etc. The Company has all necessary
franchises, licenses, certificates and other authorizations from any applicable government or governmental agency, department, or body that are currently necessary for the operation of the business of the Company as currently conducted and as
described in the ASX Documents (as defined in Section 3.9 hereof), except where the failure to currently possess such would not have a Material Adverse Effect. 
 3.5     No Conflicts. The execution, delivery and performance of this Agreement by the Company and the consummation by the
Company of the transactions contemplated hereby do not and will not (i) conflict with or violate any provision of the Company’s or any of its Subsidiaries’ certificates or articles of incorporation, by-laws or other organizational or
charter documents, (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation (with or
without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any of its Subsidiaries is a party or by which
any property or asset of the Company or any of its Subsidiaries is bound or affected, or (iii) result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority
to which the Company or any of its Subsidiaries is subject (including federal and state securities laws and regulations), or by which any property or asset of the Company or any of Subsidiaries is bound or affected; except in the case of each of
clauses (ii) and (iii), such as would not, individually or in the aggregate, have a Material Adverse Effect. 
 3.6     Filings, Consents and Approvals. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice to, or make any filing or registration with, any court or other
federal, state, local or other governmental authority or other Person in connection with the execution, deliver and performance by the Company of this Agreement, other than filings with the Commission, filings pursuant to applicable state securities
laws and Regulation D, and with the ASX required by the Exchange Act, the Corporations Act and the Listing Rules, respectively, as a result of the transactions contemplated hereby, and those that have been made or obtained prior to the date of this
Agreement. 

 3.7     Issuance of the Shares; Capitalization. 
 (a)     Upon receiving the Stockholder Approval, the Shares to be issued at the Closing will be duly authorized for issuance and sale
to the Investors pursuant to this Agreement, and, when issued and delivered by the Company pursuant to this Agreement against payment of the consideration set forth herein, the Shares will be duly and validly issued and fully paid and
non-assessable. 
 (b)     Upon receiving the Stockholder Approval, the Warrant Shares will be duly and validly
authorized and reserved for issuance upon exercise of the Warrants, including the reservation of a sufficient number of shares of Common Stock for all Warrant Shares, and, when issued and delivered by the Company to the holder of such Warrant
against payment of the consideration set forth therein, the Warrant Shares will be duly and validly issued and fully paid and non-assessable. 
 (c)     All of the shares of the Company’s Common Stock issued prior to the date of this Agreement have been duly and validly issued and are fully paid and non-assessable, have been issued in compliance with all
applicable securities laws, and were not issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities. 
 (d)     Without limiting any other representations set forth in this Agreement, no preemptive right, co-sale right, right of first refusal or other similar right exists with respect to the Shares or the issuance and sale
thereof. There are no stockholders agreements, voting agreements or other similar agreements with respect to the Company’s capital stock to which the Company is a party or, to the knowledge of the Company, between or among any of the
Company’s stockholders. The issuance and sale of the Shares will not result in a right of any current holder of Company securities to adjust the exercise, conversion, exchange or reset price under such securities. Except for options issued to
officers, directors, employees and consultants of the Company under its employee benefit plans or as otherwise set forth in the ASX Documents, there are no outstanding rights (including, without limitation, preemptive rights), warrants or options to
acquire, or instruments convertible into or exchangeable for, any unissued shares of capital stock or other equity interest in the Company, or any contract, commitment, agreement, understanding or arrangement of any kind to which the Company is a
party or of which the Company has knowledge and relating to the issuance or sale of any capital stock of the Company, any such convertible or exchangeable securities or any such rights, warrants or options. 
 3.8     Secondary Sales. The Case 1 exemption in section 708A(5) of the Corporations Act applies in relation to the Shares
issued under this Agreement and: 
 (a)     the Shares issued under this Agreement are in a class of securities that are
capable of conversion into CDIs of the Company which: 
 (i)     are quoted securities (as defined in the Corporations
Act) of the Company at all times in the three (3) months before the date of issue; and 
 (ii)     have been quoted
on a financial market operated by ASX without being suspended from trading for more than a total of five (5) trading days during the shorter of the period during which the class of securities were quoted, and the period of twelve
(12) months before the date of issue of the Shares issued under this Agreement. 

 (b)     no exemption under section 111AS or 111AT of the Corporations Act or order
under sections 340 or 341 of the Corporations Act, does or will cover the Company, or any Person, as a director or auditor of the Company, at any time in the relevant period referred to in paragraph (a)(ii); 
 (c)     ASIC has not, and will not before the date of issue of the Shares issued under this Agreement, make a determination for
contravention by the Company within the previous twelve (12) months of any of the provisions listed in section 708A(2) of the Corporations Act; and 
 (d)     each offer for sale and each sale of Shares under this Agreement will not be an offer or sale to which sections 707(3) or 707(4) of the Corporations Act applies so as to require the offeror
or seller to prepare and lodge with ASIC a prospectus or other document relating to the offer or sale. 
 3.9    
Continuous Disclosure; Reporting Status. The Company has complied with the continuous disclosure requirements under the Listing Rules and has made or lodged all required disclosures with the ASX (the “ASX Documents”), other
than the disclosures set forth on Schedule 1 hereto, which disclosures will be made in compliance with the Listing Rules. The information contained in all of the Company’s continuous disclosures, periodic disclosures, and particular
disclosures under the Listing Rules, as of the date of each such disclosure, did not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein in light
of the circumstances under which they were made not misleading. 
 3.10     Financial Statements. 
 (a)     The financial statements lodged by the Company with ASX in accordance with the Listing Rules on February 15, 2008
(i) give a true and fair view of the financial position, assets, liabilities and profits and losses of the Company as at the relevant balance date and are not misleading or deceptive in any material respect and (ii) present fairly, in
accordance with US Generally Accepted Accounting Principles (“GAAP”), the financial position of the Company as of the dates indicated, and the results of its operations and cash flows for the periods therein specified consistent
with the books and records of the Company except that the unaudited interim financial statements, if any, were or are subject to normal and recurring year-end adjustments that are not expected to be material in amount. All financial statements
lodged by the Company with ASX in accordance with the Listing Rules, have been prepared in accordance with GAAP applied on a consistent basis throughout the periods therein specified, except as may be disclosed in the notes to such financial
statements and except as disclosed in the ASX Documents, as applicable. The other financial information contained in the ASX Documents has been prepared on a basis consistent with the financial statements of the Company. As of their respective
dates, the financial statements of the Company included in the ASX Documents complied as to form in all material respects with applicable accounting requirements and published rules and regulations of the ASX with respect thereto. 
 (b)     Except as set forth in any ASX Documents or Schedule 1 hereto, there are no obligations of the Company to officers,
directors, stockholders or employees of the Company or its subsidiaries other than (i) for payment of salary for services rendered and for bonus payments; (ii) reimbursements for reasonable expenses incurred on behalf of the Company; and
(iii) for other standard employee benefits made generally available to all employees (including stock option 

 
agreements outstanding under any stock option plan approved by the Board of Directors of the Company). 
 3.11     Absence of Certain Changes. Since December 31, 2007, except as set forth in any ASX Documents or set forth on
Schedule 1 hereto, there has been no event, occurrence or development that has had or that would reasonably be expected to result in a Material Adverse Effect, and the Company has not (i) varied its business plan or practices, in any
material respect, from past practices, except for the proposed acquisition of Neosil, Inc., as announced by the Company on June 10, 2008, (ii) entered into any material financing, joint venture, license or similar arrangements or
(iii) suffered or permitted to be incurred any liability or obligation against any of its properties or assets that would limit or restrict its ability to perform its obligations hereunder. 
 3.12     Absence of Litigation; Disagreements with Advisors. There is no Proceeding before or brought by any court or
governmental agency or body, domestic or foreign, now pending, or, to the knowledge of the Company, threatened against the Company or any of its Subsidiaries, or, to the knowledge of the Company, otherwise involving the Company or any of its
Subsidiaries which could reasonably be expected to result in a Material Adverse Effect, or which could reasonably be expected to materially and adversely affect the consummation of the transactions contemplated in this Agreement or the performance
by the Company of its obligations hereunder; the aggregate of all pending legal or governmental proceedings to which the Company or any of its Subsidiaries is a party or of which any of their respective property or assets is the subject, including
ordinary routine litigation incidental to the Company’s conduct of its business, would not be reasonably likely to result in a Material Adverse Effect. There are no material disagreements presently existing between the accountants formerly or
presently employed by the Company. 
 3.13     Securities Laws. Assuming that the representations of each of the
Investors set forth in Article IV below are true and correct, the offer, sale, and issuance of the Units in conformity with the terms of this Agreement are exempt from the registration and prospectus delivery requirements of the Securities
Act and from the securities registration and qualification requirements of the currently effective provisions of the securities laws of the states in which the Investors are resident, based upon their addresses set forth on Exhibit A, and
neither the Company nor any authorized agent acting on its behalf will take any action hereafter that would cause the loss of such exemptions. Neither the Company nor any of its officers, employees, agents, directors or stockholders has
(i) engaged in any “general solicitation,” as defined in Regulation D promulgated under the Securities Act, (ii) “published” any “advertisement,” as defined in the California Corporate Securities Act of 1968,
as amended, and the regulations thereunder or (iii) offered the Units to any person who is not an “accredited investor,” as defined in the Securities Act, in connection with the offer and sale of the Units, other than non-U.S. Persons
in compliance with Regulation S promulgated under the Securities Act. Except in compliance with Regulation D promulgated under the Securities Act, neither the Company nor any of its officers, employees, agents, directors, stockholders or any persons
acting on the Company’s behalf, has engaged or will engage in any directed selling efforts (as defined in Regulation S promulgated under the Securities Act) in the United States in connection with the offer and sale of the Shares. 

3.14     Underwriting Fee. No agent, broker, underwriter, investment banker, financial advisor or other firm or Person is
or will be entitled to any broker’s or finder’s fee or any other similar commission or fee in connection with any of the transactions contemplated by this Agreement based upon arrangements made by or on behalf of the Company. 

 3.15     Intellectual Property. Except as specifically disclosed in the ASX
Documents (i) the Company owns or possesses sufficient rights to use all patents, patent rights, trademarks, copyrights, licenses, inventions, trade secrets, trade names and know-how (including trade secrets and other unpatented and/or
unpatentable property or confidential information, systems, processes or procedures) (collectively, “Intellectual Property”) described or referred to in the ASX Documents as owned or possessed by them or that are necessary for the
conduct of its business as now conducted as described in the ASX Documents except where the failure to currently own or possess would not have a Material Adverse Effect, (ii) to its knowledge, the Company is not infringing, and has not received
any notice of any asserted infringement by the Company of any rights of a third party with respect to any Intellectual Property that, individually or in the aggregate, would have a Material Adverse Effect and (iii) the Company has not received
any notice of, and has no knowledge of, infringement by a third party with respect to any Intellectual Property rights of the Company, individually or in the aggregate, would have a Material Adverse Effect. 
 3.16     Disclosure. The representations and warranties of the Company contained in this Section 3, as of the date
hereof and as of the Closing Date, do not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were
made, not misleading. 
 3.17     Company not an “Investment Company”. The Company has been advised of
the rules and requirements under the United States Investment Company Act of 1940, as amended (the “Investment Company Act”). The Company is not, and immediately after receipt of payment for the Shares will not be, an
“investment company” or an entity “controlled” by an “investment company” within the meaning of the Investment Company Act and shall conduct its business in a manner so that it will not become subject to the Investment
Company Act. 
 3.18     Foreign Corrupt Practices. Neither the Company, nor to the knowledge of the Company, any
agent or other person acting on behalf of the Company, has (i) directly or indirectly, used any corporate funds for unlawful contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity,
(ii) made any unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate funds, (iii) failed to disclose fully any contribution made by the Company
(or made by any person acting on its behalf of which the Company is aware) which is in violation of law, or (iv) violated in any material respect any provision of the United States Foreign Corrupt Practices Act of 1977, as amended. 

3.19     Taxes. The Company has filed (or has obtained an extension of time within which to file) all necessary federal,
state and foreign income and franchise tax returns and has paid all taxes shown as due on such tax returns, except where the failure to so file or the failure to so pay would not have a Material Adverse Effect. No material controversy with respect
to taxes of any type with respect to the Company is pending or, to the Company’s knowledge, threatened. The Company has withheld or collected from each payment made to its employees the amount of all taxes required to be withheld or collected
therefrom and has paid all such amounts to the appropriate taxing authorities when due. The Company is not aware of any tax deficiency that has been or might be asserted or threatened against it that would have a Material Adverse Effect. 

3.20     Benefits. The Company has fulfilled its obligations, if any, under the minimum funding standards of
Section 302 of the United States Employee Retirement Income Security Act of 1974 (“ERISA”) and the regulations and published interpretations thereunder with respect to each 

 
“plan” as defined in Section 3(3) of ERISA and such regulations and published interpretations in which its employees are eligible to
participate and each such plan is in compliance in all material respects with the presently applicable provisions of ERISA and such regulations and published interpretations. No “Reportable Event” (within the meaning of Section 4043
of ERISA) has occurred with respect to any “Employee Benefit Pension Plan” (as defined in Section 3(2) of ERISA) for which the Company could have any liability. The Company has never maintained, established, sponsored, participated
in, or contributed to, any “plan” (as defined in Section 3(3) of ERISA), subject to Section 210 of ERISA.  
 ARTICLE IV 
 REPRESENTATIONS AND WARRANTIES OF THE INVESTORS 
 Each Investor, severally for itself, and not jointly with the other Investors, represents and warrants to the Company, that as of the date of this
Agreement and as of the Closing Date: 
 4.1     Organization; Authority. Such Investor (i) if a legal
entity, is an entity duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization and (ii) has the requisite corporate or partnership power and authority, as applicable, to enter into and to
consummate the transactions contemplated hereby and otherwise to carry out its obligations hereunder. The execution, delivery and performance of the transactions contemplated by this Agreement have been duly authorized by all necessary corporate or,
if such Investor is not a corporation, such partnership, limited liability company or other applicable like action, on the part of Investor. This Agreement has been duly executed such Investor, and when delivered by such Investor in accordance with
the terms hereof, will constitute the valid and legally binding obligation of such Investor, enforceable against it in accordance with its terms, except (i) as such enforceability may be limited by applicable bankruptcy, insolvency,
reorganization, moratorium, liquidation or similar laws relating to, or affecting generally the enforcement of, creditors’ rights and remedies or by other equitable principles of general application affecting enforcement of creditors’
rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable
law. 
 4.2     Experience of Investor. Such Investor has such knowledge, sophistication and experience in
business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Units, and has so evaluated the merits and risks of such investment. Such Investor is able to bear the economic risk of an
investment in the Units and, at the present time, is able to afford a complete loss of such investment. 
 4.3    
General Solicitation. Such Investor is not purchasing the Units as a result of any advertisement, article, notice or other communication regarding the Units published in any newspaper, magazine or similar media or broadcast over television or
radio or presented at any seminar or any other general solicitation or general advertisement or as a result of any filing by the Company with the Commission, and such Investor did not see or become aware of any advertisement, article, notice or
other communication regarding the Units published in any newspaper, magazine or similar media or broadcast over television or radio or presented at any seminar or any other general solicitation or general advertisement prior to July 9, 2008.
Such Investor understands and acknowledges that its discussions with the Company and any other written information provided by the Company, if any, (i) were intended to describe the aspects of the 

 
Company’s business and prospects which the Company believes to be material, but were not necessarily an exhaustive description and (ii) may have
contained forward-looking statements involving known and unknown risks and uncertainties which may cause the Company’s actual results in future periods or plans for future periods to differ materially from what was anticipated and that no
representations or warranties were or are being made with respect to any such forward-looking statements or the probability of achieving any of the results projected in any of such forward-looking statements. 
 4.4     Access to Information. Such Investor acknowledges that it has been afforded (i) the opportunity to ask such
questions as it has deemed necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the Units and the merits and risks of investing in the Units, (ii) adequate access to
information about the Company and its Subsidiaries and their respective financial condition, results of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment and (iii) the opportunity to
obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense that is necessary to make an informed investment decision with respect to the investment. 
 4.5     Governmental Review. Such Investor understands that no United States federal or state agency or any other government
or governmental agency, whether domestic or foreign, has passed on or made any recommendation or endorsement of the Securities or the fairness or suitability of the investment in the Securities nor have such authorities passed upon or endorsed the
merits of the offering of the Securities. 
 4.6     Status of Investor. Such Investor is either (i) an
“accredited investor” within the meaning of the Rule 501 of Regulation D, as presently in effect, under the Securities Act or (ii) a “non-U.S. Person” within the meaning of Rule 902(k) of Regulation S. If such Investor is a
non-U.S. Person, such Investor further represents that: 
 (a) Such Investor (i) is not a “U.S. Person” and is not acquiring
the Units for the account of any “U.S. Person,” (ii) no director or executive officer of such Investor is a national or citizen of the United States and (iii) such Investor is not otherwise deemed to be a “U.S. Person”
within the meaning of Rule 902(k) of Regulation S. 
 (b) Such Investor is either a “Sophisticated Investor” within the meaning of
section 708(8) or a “Professional Investor” within the meaning of section 708(11) of the Corporations Act. 
 (c) Such Investor was
not formed specifically for the purpose of acquiring the Units purchased pursuant to this Agreement. 
 (d) Such Investor acknowledges that
it will not be afforded the protection of Section 11 of the Securities Act and that, pursuant to Regulation S, the Units may not be transferred, sold or otherwise exchanged unless in compliance with the provisions of Regulation S, pursuant
to registration under the Securities Act, or pursuant to an available exemption thereunder. 
 (e) Such Investor agrees that it will neither
offer nor sell any Shares or Warrant Shares during the Distribution Compliance Period to “U.S. Persons.” Such Investor will, after the expiration of the Distribution Compliance Period, offer, sell, pledge or otherwise transfer any of the
Shares or Warrant Shares only in accordance with Regulation S, following the effective date of a 

 
registration statement registering the resale of the Shares and Warrant Shares, or pursuant to an available exemption under the Securities Act and, in any
case, in accordance with applicable state securities laws. The transactions contemplated by this Agreement have neither been pre-arranged with a purchaser who is in the United States or who is a “U.S. Person,” nor are they part of a plan
or scheme to evade the registration provisions of the United States federal securities laws. 
 (f) Such Investor agrees that it will not
engage in any hedging transition with respect to the Shares or Warrant shares, except in compliance with the Securities Act. 
 (g) The offer
leading to the sale evidenced hereby was made in an “offshore transaction.” For purposes of Regulation S, such Investor understands that an “offshore transaction,” as defined under Regulation S, is any offer or sale not
made to a person in the United States and either (i) at the time the buy order is originated, the purchaser is outside the United States, or the seller or any person acting on his behalf reasonably believes that the purchaser is outside the
United States or (ii) for purposes of (A) Rule 903 of Regulation S, the transaction is executed in, or on or through a physical trading floor of an established foreign exchange that is located outside the United States or
(B) Rule 904 of Regulation S, the transaction is executed in, on or through the facilities of a designated offshore securities market, and neither the seller nor any person acting on its behalf knows that the transaction has been
prearranged with a buyer in the United States. 
 (h) Neither such Investor nor any affiliate or any Person acting on such Investor’s
behalf, has made or is aware of any “directed selling efforts” in the United States, as defined in Rule 902(c) of Regulation S. 
 (i) Such Investor understands that the Company is the seller of the Units which are the subject of this Agreement, and that, for purpose of Regulation S, a “distributor” is any underwriter, dealer or other Person who
participates, pursuant to a contractual arrangement, in the distribution of securities offered or sold in reliance on Regulation S and that an “affiliate” is any partner, officer, director or any Person directly or indirectly
controlling, controlled by or under common control with any person in question. Such Investor agrees that such Investor will not, during the Distribution Compliance Period set forth under Rule 903(b)(iii)(A) of Regulation S, act as a
distributor, either directly or through any affiliate, nor shall it sell, transfer, hypothecate or otherwise convey the Shares or Warrant Shares other than to a non-U.S. Person. 
 (j) Such Investor acknowledges that the Company will refuse to register any transfer of the Shares or Warrant Shares not made in accordance with the
provisions of Regulation S, pursuant to the Securities Act or pursuant to an available exemption from registration. 
 (k) Such Investor
acknowledges that until (i) the Shares or Warrant Shares may be sold in compliance with Regulation S or (ii) such time as the resale of the Shares or Warrant Shares has been registered under the Securities Act, the certificates
representing the Shares or Warrant Shares will bear a restrictive legend as set forth below in Section 4.9 (and a stop-transfer may be placed against transfer of the certificates). 
 4.8     Restricted Securities. Such Investor understands and acknowledges that the Units, including the Shares and Warrant
Shares, have not been registered under the Securities Act, are being sold in reliance upon an exemption from registration afforded by Regulation S and Regulation D, as applicable, and that the Units have not been registered with any state
securities commission or authority and that the Company is relying upon the truth and accuracy of, and such Investor’s 

 
compliance with, the representations, warranties, agreements, acknowledgments and understandings of such Investor set forth herein in order to determine the
availability of such exemption, as applicable, and the eligibility of such Investor to acquire the Units. 
 4.9    
Legends. Such Investor acknowledges that, to the extent applicable, each certificate evidencing the Shares or Warrant Shares shall be endorsed with the legends substantially in the form set forth below, as well as any additional legend
imposed or required by the Company’s by-laws or applicable state securities laws. For Shares and Warrant Shares sold in reliance of the exemption provided by Regulation D, the legend shall read as follows: 
 THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.
SUCH SHARES MAY NOT BE SOLD, TRANSFERRED, PLEDGED, ENCUMBERED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF SUCH REGISTRATION OR UNLESS THE COMPANY RECEIVES AN OPINION OF HOLDER’S COUNSEL OR OTHER EVIDENCE SATISFACTORY TO THE COMPANY AND ITS
COUNSEL THAT SUCH REGISTRATION IS NOT REQUIRED. 
 For Shares and Warrant Shares sold in reliance of the exemption provided by Regulation S, the legend shall
read as follows: 
 THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE BEEN OFFERED AND SOLD IN AN “OFFSHORE TRANSACTION” IN
RELIANCE UPON REGULATION S AS PROMULGATED BY THE SECURITIES AND EXCHANGE COMMISSION. ACCORDINGLY, THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”),
AND MAY NOT BE SOLD, TRANSFERRED, PLEDGED, ENCUMBERED OR OTHERWISE DISPOSED OF IN THE UNITED STATES, OR TO, OR FOR, THE ACCOUNT OF, OR BENEFIT OF, A U.S. PERSON, OTHER THAN DISTRIBUTORS (AS DEFINED IN REGULATION S) OTHER THAN (1) IN ACCORDANCE
WITH REGULATION S, (2) PURSUANT TO REGISTRATION UNDER THE SECURITIES ACT OR (3) PURSUANT TO AN AVAILABLE EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT, THE AVAILABILITY OF WHICH IS TO BE ESTABLISHED BY AN OPINION OF HOLDER’S
COUNSEL TO THE COMPANY, OR OTHER EVIDENCE SATISFACTORY TO THE COMPANY THAT SUCH EXEMPTION IF AVAILABLE. 
 The legends set forth above will
be removed and the Company will issue book-entry shares or a stock certificate without the legend to the holder of any certificate upon which it is stamped, in accordance with the terms of Article VII hereof. 
 4.10     Economic Risk. Such Investor understands, acknowledges and agrees that it must bear the economic risk of its
investment in the Units for an indefinite period of time and that prior to any such offer or sale, the Company may require, as a condition to effecting a transfer of the Securities, an opinion of counsel, acceptable to the Company, as to the
registration or exemption therefrom under the Securities Act and any state securities acts, if applicable. 
 4.11    
Purchase For Own Account. Such Investor is acquiring the Units for investment for such Investor’s own account, not as a nominee or agent, and not with the view to, or for resale in connection with, any distribution thereof. Such Investor
further represents that it does not have any 

 
contract, undertaking, agreement or arrangement with any person to sell, transfer or grant participation to any third person with respect to any of the
Units. 
 4.12     Section 11 Liability. Such Investor acknowledges and understands that in connection with
the issuance of the Units, it does not have the protection of Section 11 of the Securities Act. 
 4.13    
Registration Withdrawal. Such Investor understands that a registration statement for the Common Stock was filed and later withdrawn by the Company on June 9, 2008. 
 ARTICLE V 
 REGISTRATION RIGHTS 
 5.1       Company’s Obligations. 
 (a)     The Company covenants and agrees that: (i) (subject to the provisions of this Article V), it will prepare and file with the Commission, on or before November 30, 2008 (the
“Filing Deadline”), a registration statement on Form S-1 (the “Registration Statement”) registering the resale of all of Registrable Securities by the Investors in an offering to be made on a continuous basis
pursuant to Rule 415. The Company will use its commercially reasonable efforts to cause the Registration Statement to be declared effective under the Act by no later than March 30, 2009 (the “Effectiveness Deadline”), and to
keep the Registration Statement continuously effective until the earlier of (A) such time that all of the Registrable Securities have been sold pursuant to the Registration Statement and (B) such time as all the Registrable Securities held
by non-affiliates of the Company may be resold to the public in accordance with Rule 144 under the Securities Act where no conditions of Rule 144 are then applicable (other than the holding period requirement of paragraph (d) of Rule 144). If
(i) the Registration Statement is not filed with the Commission prior to or on the Filing Deadline or (ii) the Registration Statement has not been declared effective by the Commission prior to or on the Effectiveness Deadline (each such
event, a “Registration Default”), then in each such case the Company will make pro rata payments to each Investor that continues to hold Registrable Securities, as liquidated damages and not as a penalty, in an amount equal
to 1.0% per month of the aggregate purchase price paid by such Investor for each Unit then held by such Investor for each thirty (30) calendar day period following the Registration Default to but excluding the day on which such
Registration Default has been cured; provided, however that in no event shall the aggregate liquidated damages payable by the Company to the Investors exceed 12.0% of the aggregate purchase price paid by such Investor for all Common
Stock and Warrants acquired by such Investor pursuant to the Purchase Agreement. The amounts payable as liquidated damages pursuant to this paragraph shall be paid in lawful money of the United States within fifteen (15) calendar days of the
last day of each thirty (30) calendar day period following the commencement of a Registration Default until the termination of such Registration Default. In addition, the Company shall timely supplement and amend the Registration Statement if
required by the rules, regulations or instructions applicable to the registration form used for the Registration Statement or if required by the Securities Act. If (i) at any time when a prospectus relating to Registrable Securities is required
to be made available under the Securities Act, the Company discovers that, or any event occurs as a result of which, the prospectus (including any supplement thereto) included in the Registration Statement, as then in effect, includes an untrue
statement of a material fact or omits to state any material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading, or (ii) the Commission
issues any stop order suspending the effectiveness of the Registration Statement or proceedings are initiated or 

 
threatened for that purpose, then the Company shall promptly deliver a written notice to such effect to each Holder, and each Holder shall immediately upon
receipt of such notice discontinue its disposition of Registrable Securities pursuant to the Registration Statement until the copies of the supplemented or amended prospectus contemplated by the immediately following sentence is made available and,
if so directed by the Company, shall deliver to the Company (at the Company’s expense), if applicable, all copies, other than permanent file copies, then in such Holder’s possession of the prospectus or prospectus supplement relating to
such Registrable Securities current at the time of receipt of such notice. As promptly as practicable following the event or discovery referred to in clause (i) of the immediately preceding sentence, the Company shall prepare and file with the
Commission an amendment or supplement to the Registration Statement and shall prepare and make available to each Holder the corresponding amendment or supplement of such prospectus so that, as thereafter made available to purchasers of such
Registrable Securities, neither such Registration Statement nor prospectus shall include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in the light
of the circumstances under which they were made, not misleading. Notwithstanding anything to the contrary in this Article V, if the filing or maintenance of the Registration Statement would require the Company to make a disclosure that would,
in the good faith, reasonable judgment of the Company’s board of directors, have a Material Adverse Effect on the Company, the Company shall have the right, upon delivery to each Holder of a certificate executed by the Company’s chief
executive officer certifying the board of directors’ finding (a “Blackout Notice”) to delay the filing (but not the preparation) of the Registration Statement or of any amendment or supplement thereto, to suspend its obligation
to maintain the effectiveness of the Registration Statement and to suspend the use of any prospectus or prospectus supplement in connection with the Registration Statement, in each case for a reasonable amount of time not to exceed thirty
(30) days (the “Blackout Period”) within the ninety (90) day period beginning on the first day of a Blackout Period. Notwithstanding the foregoing, the Company shall not deliver any subsequent Blackout Notice or commence
any subsequent Blackout Period while any current Blackout Period is still in effect. Each Holder agrees that upon receipt of a Blackout Notice, it shall immediately cease all efforts to dispose of Registrable Securities pursuant to the Registration
Statement until such time as the Company shall notify it of the end of such restrictions or, if earlier, the expiration of the Blackout Period. 
 (b)     Notwithstanding Section 5.1(a), if the Commission prevents the Company from including any or all of the Registrable Securities on a Registration Statement due to limitations on the use of Rule 415 of
the Securities Act for the resale of the Registrable Securities by the Holders (a “Rule 415 Limitation”), the Registration Statement shall register the resale of a number of shares of Common Stock which is equal to the maximum
number of shares as is permitted by the Commission, and, subject to the provisions of this Section 5.1(b), the Company shall continue to use its commercially reasonable efforts to register all remaining Registrable Shares as set forth in
Section 5.1(a). In such event, the number of shares of Registrable Securities to be registered for each Holder in the Registration Statement shall be reduced pro rata among all Holders. The Company shall continue to use its commercially
reasonable efforts to register all remaining Registrable Shares as promptly as practicable in accordance with the applicable rules, regulations and guidance of the Commission, but in no event will the Company file a subsequent Registration Statement
with respect to the registration of the resale of Registrable Shares held by the Holders earlier than one hundred eighty (180) calendar days following the effective date of the initial Registration Statement. Notwithstanding anything herein to
the contrary, if the Commission, by written comment or otherwise, limits the Company’s ability to file, or prohibits or delays the filing of, a Registration Statement with respect to any or all the Registrable Shares (a “Subsequent
Limitation”), it shall not be a breach or default by the Company under this Agreement, shall not be deemed a failure by the 

 
Company to use “reasonable efforts,” “commercially reasonable efforts” or “best efforts” as set forth above or elsewhere in
this Agreement. 
 5.2     Registration Expenses. All expenses incident to the Company’s performance of or
compliance with this Article V will be borne by the Company; provided, however, the Company shall not bear the costs and expenses of brokerage fees or transfer taxes for any Investor, or the fees and expenses of any attorneys,
accountants or other representatives retained by any Holder other than the reasonable fees and expenses, not to exceed $10,000, incurred by a single law firm selected by the Holder(s) in connection with such law firm’s representation of such
Holder(s) in any registration effected in compliance with this Article V. 
 5.3     Indemnification.

 (a)     The Company agrees to indemnify each Holder, its officers, directors and agents and each person who
“controls” such Holder within the meaning of the Securities Act and the Exchange Act (each, an “Indemnified Holder”), against losses, claims, damages, including amounts incurred in settlement, liabilities and expenses
arising out of, based upon or resulting from any breach by the Company of any of its representations, covenants, agreements or obligations contained in this Agreement, any untrue statement or alleged untrue statement of a material fact in this
Agreement or any Registration Statement covering the Registrable Securities or any prospectus which forms a part of such Registration Statement or any omission or alleged omission to state a material fact required to be stated therein or necessary
to make the statements therein, and in the case of a prospectus, in light of the circumstances under which they were made, not misleading; provided, however, that the Company will not be liable in any such case to the extent that any
such loss, claim, damage, liability or expense arises out of or is based upon any untrue statement or omission contained in any Registration Statement covering the Registrable Securities or any prospectus which forms a part of such Registration
Statement that is based upon information furnished in writing to the Company by such Indemnified Holder or its representative expressly for the use therein. 
 (b)     Each Holder participating in a registration agrees to indemnify, severally and not jointly, the Company, its directors, officers and agents and each person who “controls” the
Company (within the meaning of the Securities Act and the Exchange Act) against losses, claims, damages, liabilities and expenses resulting from any breach by such Holder of any of its representations, covenants, agreements or obligations contained
in this Agreement, any untrue statement or alleged untrue statement of a material fact in any Registration Statement covering the Registrable Securities or any prospectus which forms a part of such Registration Statement or any omission or alleged
omission to state a material fact required to be stated therein or necessary to make the statements therein, and in the case of a prospectus, in light of the circumstances under which they were made, not misleading, to the extent, and only to the
extent, that any such loss, claim, damage, liability or expense arises out of, is based upon or results from any untrue statement (or alleged untrue statement) or omission (or alleged omission) based upon, in reliance on and in conformity in all
material respects with, information furnished in writing to the Company by such Holder or its representative expressly for use therein. In no event shall the liability of any selling Holder hereunder be greater in amount than the dollar amount of
the net proceeds received by such Holder upon the sale of the Registrable Securities giving rise to such indemnification obligation. 
 (c)     Any Person entitled to indemnification hereunder will: (i) give prompt written notice to the indemnifying party after the receipt by the indemnified party of a written notice of the commencement of any
action, suit, proceeding or investigation or threat thereof made in 

 
writing for which such indemnified party will claim indemnification or contribution pursuant to this Agreement; provided, however, that the failure of any
indemnified party to give notice as provided herein shall not relieve the indemnifying party of its obligations under the preceding Sections 5.3(a) or 5.3(b), as applicable, except to the extent that the indemnifying party is actually
and materially prejudiced by such failure to give notice, and (ii) unless in such indemnified party’s reasonable judgment a conflict of interest may exist between such indemnified and indemnifying parties with respect to such claim, permit
such indemnifying party to assume the defense of such claim with counsel reasonably satisfactory to the indemnified party. Whether or not such defense is assumed by the indemnifying party, the indemnifying party will not be subject to any liability
for any settlement made without its consent (but such consent will not be unreasonably withheld). No indemnifying party will be required to consent to the entry of any judgment or to enter into any settlement, unless such judgment or settlement is
solely for monetary damages and includes an unconditional release from all liability in respect of such claim or litigation in favor of the indemnifying party. Any indemnifying party who is not entitled to, or elects not to, assume the defense of a
claim will not be obligated to pay the fees and expenses of more than one counsel in any one jurisdiction for all parties indemnified by such indemnifying party with respect to such claim. 
 (d)     If for any reason the indemnification provided for in Sections 5.3(a) or 5.3(b), as applicable, is unavailable
to an indemnified party as contemplated by such section, then the indemnifying party, in lieu of indemnification, shall contribute to the amount paid or payable by the indemnified party as a result of such loss, claim, damage, liability or expense
in such proportion as is appropriate to reflect not only the relative benefits received by the indemnified party and the indemnifying party, but also the relative fault of the indemnified party and the indemnifying party, as well as any other
relevant equitable considerations; provided, however, that in no event shall the liability of any selling Holder under this Section 5.3(d) be greater in amount than the dollar amount of the net proceeds received by such
Holder upon the sale of the Registrable Securities giving rise to such indemnification obligation. 
 5.4    
Holders’ Obligations. In connection with the registration rights granted pursuant to this Article V, each Holder shall: 
 (a)     furnish to the Company such information regarding itself, the Registrable Securities held by it and the intended method of disposition of the Registrable Securities held by it as is reasonably required by the
Company to effect the registration of the Registrable Securities at least ten (10) Business Days prior to the first anticipated filing date of a Registration Statement for any registration under this Agreement; 
 (b)     cooperate with the Company, as reasonably requested by the Company, in connection with the preparation and filing of any
Registration Statement hereunder, unless such Holder has notified the Company in writing of such Holder’s election to exclude all of such Holder’s Registrable Securities from the Registration Statement; 
 (c)     comply with the prospectus delivery requirements of the Securities Act as applicable to it or an exemption therefrom in
connection with sales of Registrable Securities pursuant to a Registration Statement; and 
 (d)     if participating in
an underwritten public offering, enter into and perform such Holder’s obligations under an underwriting agreement, in usual and customary form, including, without limitation, customary indemnification and contribution obligations, with the
managing 

 
underwriter of such offering, and will take such other actions as are reasonably required in order to expedite or facilitate the disposition of the
Registrable Securities, unless such Holder has notified the Company in writing of such Holder’s election to exclude all of its Registrable Securities from such Registration Statement. 
 ARTICLE VI 
 OTHER AGREEMENTS OF THE PARTIES 
 6.1     Short Sales. Each Investor has, not directly or indirectly, nor has any Person acting on behalf of or pursuant to any
understanding with such Investor, executed any Short Sales in the securities of the Company, nor will any Investor, at any time, use any of the Securities to cover any short position in the Common Stock. Additionally, each Investor understands and
acknowledges that the Commission currently takes the position that coverage of short sales of the Common Stock “against the box” prior to the effective date of the Registration Statement issuable hereunder is a violation of Section 5
of the Securities Act, as set forth in Item 65 under Section A, of the Manual of Publicly Available Telephone Interpretations, dated July 1997, compiled by the Office of Chief Counsel, Division of Corporation Finance. 
 6.2     Other obligations of the Company. The Company shall: 
 (a)     upon the execution of this Agreement, make an announcement on the ASX Announcements Platform regarding the execution of this
Agreement; 
 (b)     in relation to any Securities issued under this Agreement, give to ASX, as soon as practicable
following the relevant issue, an Appendix 3B notifying ASX of the issue of Securities which has been made in accordance with the Listing Rules; and 
 (c)     at such time as (i) the Registrable Securities may be sold pursuant to a Registration Statement or (ii) all Registrable Securities held by non-affiliates of the Company may be resold to the public in
accordance with Rule 144 under the Securities Act where no conditions of Rule 144 are then applicable (other than holding the holding period requirement of paragraph (d), which holding period requirement must be satisfied at such time), the Company
shall, if requested in writing by any Investors who have or intend to convert their Shares to CDIs (and subject to applicable law) apply for the quotation of such CDIs on ASX no later than five (5) Business Days after the date of such notice in
accordance with the Listing Rules, with the Company being responsible to pay all fees, costs and expenses associated with such application for quotation and with listing on ASX. 
 6.3     Investor Designee. Immediately following the Closing, the Company shall use its best efforts to nominate and cause to
be appointed as a Class II director on the Company’s board of directors, one individual designated by GBS Venture Partners Pty (the “Investor Designee”). The initial Investor Designee shall be Dr. Joshua Funder.

 ARTICLE VII 
 TRANSFER AGENT INSTRUCTIONS; REMOVAL OF LEGENDS 
 7.1     Book Entry /
Certificate Delivery. The Company will, or will instruct its transfer agent to, (i) at the Closing, issue book-entry shares of stock or, if requested by such Investor, prepare and deliver a stock certificate, representing the shares issued
in the name of, and registered to the account of, each Investor on the records of the Company’s transfer agent for its Common Stock, and (ii) upon exercise of a Warrant by an Investor, in accordance with its terms, issue book-entry shares
of stock or, if requested by such Investor, prepare and deliver a stock certificate, representing Warrant Shares, issued in the name of, and registered to the account of, such Investor, on the records of the Company’s transfer agent for its
Common Stock. All such book-entry shares or stock certificates will bear the applicable restrictive legend described in Section 4.9, except as otherwise specified in this Article VII. The Company will not give to its transfer
agent any instruction other than as described in this Article VII and stop transfer instructions to give effect to Section 4.7(i) hereof (prior to registration of the Shares or Warrant Shares under the Securities Act). Nothing in
this Article VII affects in any way such Investor’s obligations to comply with all applicable prospectus delivery requirements, if any, upon resale of the Shares or Warrant Shares. 
 7.2     Unrestricted Securities. If, unless otherwise required by applicable state securities laws, (i) the Shares or
Warrant Shares represented by a book-entry shares or certificates have been registered under an effective Registration Statement filed under the Securities Act, (ii) a Holder of Shares or Warrant Shares provides the Company and its transfer
agent with an opinion of counsel, in form, substance and scope customary for opinions of counsel in comparable transactions, to the effect that a public sale or transfer of such shares may be made without registration under the Securities Act and
such sale either has occurred or may occur without restriction on the manner of such sale or transfer, (iii) such Holder provides the Company and its transfer agent with reasonable assurances that the Holder has sold such Shares or Warrant
Shares under Regulation S, if applicable, or (iv) the Shares or Warrant Shares represented by a certificate can be sold without restriction as to the number of securities sold under Regulation S, if applicable, the Company will (x) in the
event of (i) or (ii) above, authorize its transfer agent to remove any restrictive legend relating to the transferability of such securities under the Securities Act, (y) in the event of (i) or (ii) above, permit the
issuance to such Holder of replacement book-entry shares or a stock certificate representing such shares without any such restrictive legend and (z) permit the transfer of the Shares or Warrant Shares by such Holder to a third party, upon such
Holder’s request. 
 ARTICLE VIII 
 CONDITIONS PRECEDENT; TERMINATION 
 8.1     Conditions Precedent to the
Obligations of the Company. The obligation of the Company to issue and sell the Units to each Investor at the Closing is subject to the satisfaction by such Investor, on or before the Closing Date, of each of the following conditions. These
conditions are for the Company’s sole benefit and may be waived by the Company at any time in its sole discretion. 
 (a)       The Company shall have obtained the Stockholder Approval. 
 (b)       The representations and warranties of such Investor must be true and correct in all material respects as of the Closing Date as though made at that time (except for representations 

 
and warranties that speak as of a specific date, which representations and warranties must be true and correct as of such date). 
 (c)       Such Investor shall have performed, satisfied and complied in all material respects with each covenant, agreement
and condition required by this Agreement to be performed, satisfied or complied with by such Investor at or prior to the Closing. 
 (d)       No statute, rule, regulation, executive order, decree, ruling or injunction will have been enacted, entered, promulgated or endorsed by or in any court or governmental authority of competent
jurisdiction or any self-regulatory organization having authority over the matters contemplated hereby which prohibits the consummation of any of the transactions contemplated by this Agreement, and which could, individually or in the aggregate,
have a Material Adverse Effect. 
 (e)       Each Investor shall have executed and delivered to the Company, an
officers certificate, signed by an authorized officer of such Investor, representing to the Company that the representations and warranties of such Investor made in Section 4 hereof are true and correct as of the Closing. 
 8.2     Conditions Precedent to the Obligations of each Investor. The obligation of each Investor to purchase the Units from
the Company at the Closing is subject to the satisfaction, on or before the Closing Date, of each of the following conditions. These conditions are for each Investor’s benefit and may be waived by each Investor at any time in its sole
discretion. 
 (a)       The Company shall have obtained the Stockholder Approval. 
 (b)       The aggregate proceeds to be received by the Company from all Investors pursuant to this Agreement shall be at
least $23,000,000. 
 (c)       The representations and warranties of the Company must be true and correct in
all material respects as of the Closing Date as though made at that time (except for representations and warranties that speak as of a specific date, which representations and warranties must be true and correct as of such date). 
 (d)       The Company shall have performed, satisfied and complied in all material respects with each covenant, agreement
and condition required hereby to be performed, satisfied or complied with by the Company at or prior to the Closing. 
 (e)       None of the following shall have occurred prior to the Closing: 
 (i)       adoption by the Company’s board of directors of any resolution to effect the winding up of the Company or the commencement of any proceeding against the Company for its winding up and such
proceeding is not dismissed or withdrawn before the Closing Date; 
 (ii)       the Company suspends payment
of its debts generally; or 
 (iii)       any event or condition which has or will have a Material Adverse
Effect on the Company. 
 (f)       No statute, rule, regulation, executive order, decree, ruling or injunction
will have been enacted, entered, promulgated or endorsed by or in any court or governmental authority of 

 
competent jurisdiction or any self-regulatory organization having authority over the matters contemplated hereby which prohibits the consummation of any of
the transactions contemplated by this Agreement, and which could, individually or in the aggregate, have a Material Adverse Effect. 
 (g)         The Company shall have provided to the Investors a certificate signed by an officer of the Company, dated as of the Closing Date, stating that the conditions referred to above in
Section 8.2(a) – (f) have been satisfied. 
 (h)         The Company
shall have executed and delivered a registration rights agreement, in the form attached hereto as Exhibit C, for execution by those certain Investors named therein. 
 (i)         Latham & Watkins LLP, counsel to the Company, shall have provided to the Investors, in a
form reasonably acceptable to the Investors, a signed copy of a legal opinion containing the statements set forth on Exhibit D hereto. 
 8.3     Termination. 
 (a)         The obligations of the
parties under this Agreement shall terminate (i) upon mutual written consent of the parties, or (ii) if the Stockholder Approval has not been obtained by October 31, 2008, unless extended by mutual written consent of the parties prior
to such date. 
 (b)         In the event of termination by any Investor of its obligations to effect
the Closing pursuant to this Article VIII (such Investor, a “Non-Participating Investor”), written notice thereof shall forthwith be given by the Non-Participating Investor to the Company and the other Investors, and each
other Investor shall have the right (but not the obligation) to purchase a pro rata portion of the Non-Participating Investor’s allocated portion of the total number of Units to be acquired by all Investors under this Agreement (or such
greater portion of the Non-Participating Investor’s allocated portion of the Units as otherwise agreed to among each of the other Investors electing to purchase a portion of the Non-Participating Investor’s allocated portion of the Units).
Nothing in this Article VIII shall be deemed to terminate the Company’s other obligations under this Agreement and the transactions contemplated hereby, or to release any party from any liability for any breach by such party of the terms
and provisions of this Agreement. 
 ARTICLE IX 
 MISCELLANEOUS 
 9.1     Fees and Expenses. Each of the parties shall pay
the fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation, execution, delivery and performance of this Agreement and the transactions
contemplated hereby; provided, however, that the Company shall pay up to an amount equal to $22,500 of the reasonable fees and expenses incurred by Bingham McCutchen LLP, counsel to certain of the Investors based in the United States,
incident to the negotiation, preparation, execution, delivery and performance of this Agreement and the transactions contemplated hereby. 
 9.2     Governing Law; Jurisdiction; Jury Trial Waiver. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed and enforced in
accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party hereto hereby irrevocably submits to the 

 
exclusive jurisdiction of the United States federal and state courts located in the State of New York for the adjudication of any dispute hereunder or in
connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any Proceeding, any claim that it is not personally subject to the jurisdiction of any such court, or
that such Proceeding has been commenced in an improper or inconvenient forum. Each party hereto hereby irrevocably waives personal service of process and consents to process being served in any such Proceeding by mailing a copy thereof via
registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and
notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. EACH PARTY HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT THAT IT MAY
HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR WITH ANY TRANSACTION CONTEMPLATED HEREBY. If either party shall commence a Proceeding to enforce any provisions of this
Agreement, then the prevailing party in such Proceeding shall be reimbursed by the other party for its reasonable attorneys’ fees and other costs and expenses incurred with the investigation, preparation and prosecution of such Proceeding.

 9.3     Counterparts; Signatures by Facsimile. This Agreement may be executed in several counterparts, all of
which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party, it being understood that all parties need not sign the same
counterpart. In the event that any signature is delivered by facsimile transmission, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as
if such facsimile signature page were an original thereof. 
 9.4     Headings. The headings of this Agreement are
for convenience of reference only, are not part of this Agreement and do not affect its interpretation. 
 9.5    
Severability. If any provision of this Agreement is invalid or unenforceable under any applicable statute or rule of law, then such provision will be deemed modified in order to conform with such statute or rule of law. Any provision hereof
that may prove invalid or unenforceable under any law will not affect the validity or enforceability of any other provision hereof. 
 9.6     Entire Agreement. This Agreement, together with the exhibits and schedules hereto, contain the entire understanding of the parties with respect to the subject matter hereof and supersede all prior
agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules. 
 9.7     Amendments; Waivers. No provision of this Agreement may be waived or amended except in a written instrument signed, in the case of an amendment, by the Company and the Investors or,
in the case of a waiver, by the party against whom enforcement of any such waiver is sought. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future
or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of either party to exercise any right hereunder in any manner impair the exercise of any such right.

 9.8       Notices. Any and all notices or other communications or
deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on the earliest of (i) the date of transmission, if such notice or communication is delivered via facsimile (provided the
sender receives a machine-generated confirmation of successful transmission) at the facsimile number specified in this section prior to 6:30 p.m. (New York Time) on a Business Day, (ii) the next Business Day after the date of transmission, if
such notice or communication is delivered via facsimile at the facsimile number specified in this section on a day that is not a Business Day or later than 6:30 p.m. (New York Time) on any Business Day, (iii) the Business Day following the date
of mailing, if sent by U.S. nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to be given. The address for such notices and communications shall be as follows: 

 

			
	If to the Company:	  	 Philip Moody
 Chief Financial Officer
 Peplin, Inc.
 6475 Christie Avenue
 Emeryville, CA 94608
 Fax: (510) 653-9704

		
	With a copy to:	  	 B. Shayne Kennedy
 Latham & Watkins
LLP
 650 Town Center Drive, 20th Floor
 Costa Mesa, CA 92626
 Fax: (714) 755-8290

 All correspondence to the Investors shall be sent to such Investors at their respective address
set forth on Exhibit A. 
 Each party will provide written notice to the other parties of any change in its address in accordance with
the notice provisions hereof. 
 9.9       Successors and Assigns. This Agreement shall be binding upon
and inure to the benefit of the parties and their successors and permitted assigns. The Investors may not assign this Agreement without the prior written consent of the Company, which may be given in its sole discretion. 
 9.10     No Third Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective
permitted successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other person. 
 9.11     Further Assurances. Each party will do and perform, or cause to be done and performed, all such further acts and things, and will execute and deliver all other agreements, certificates, instruments and
documents, as another party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby. 

 9.12     No Strict Construction. The language used in this Agreement is deemed
to be the language chosen by the parties to express their mutual intent, and no rules of strict construction will be applied against any party. 
 9.13     No Merger. No terms of this Agreement merge on the issue of any Shares or Warrants. 
 9.14     Limitation of Liability and Obligations. 
   (a)      
Subject to Section 9.14(c), GBS Venture Partners Pty Ltd enters into this Agreement only in its capacity as trustee of the GBS BioVentures IV Trust (the “Trust”) and in no other capacity. A liability arising under or in
connection with this Agreement is limited to, and can be enforced against GBS Venture Partners Pty Ltd only to the extent to which it can be satisfied out of the assets of the Trust out of which GBS Venture Partners Pty Ltd is actually indemnified
for the liability. This limitation of GBS Venture Partners Pty Ltd’s liability applies despite any other provision of this Agreement and extends to all liabilities and obligations of GBS Venture Partners Pty Ltd in any way connected with any
representation, warranty, conduct, omission, agreement or transaction related to this Agreement. 
   (b)       Subject to Section 9.14(c), no party may sue GBS Venture Partners Pty Ltd in any capacity other than as trustee of the Trust, including seek the appointment of a receiver
(except in relation to property of the Trust), a liquidator, an administrator, or any similar person to GBS Venture Partners Pty Ltd or prove in any liquidation, administration or arrangement of or affecting GBS Venture Partners Pty Ltd (except in
relation to property of the Trust). 
   (c)       The provisions of Sections 9.14(a) and
(b) do not apply to any obligation or liability of GBS Venture Partners Pty Ltd to the extent that it is not satisfied because under the deed governing the Trust, or by operation of law, there is a reduction in the extent of GBS Venture
Partners Pty Ltd’s indemnification out of the assets of the Trust, as a result of GBS Venture Partners Pty Ltd’s fraud, negligence or breach of trust. 
 9.15     No Limitation Additional Registrations. Nothing in this Agreement shall limit, in any respect, the Company’s ability to (i) file one or more registration statements with
the Commission, registering the resale of any other securities of the Company that are, or may become, outstanding, or (ii) include such other securities on the registration statement contemplated in Section 5.1 hereto. 

[Signature page follows] 

 IN WITNESS WHEREOF, the Company and the undersigned Investor have caused this Agreement to be duly
executed as of the date first above written. 
  

			
	 COMPANY:
  
 PEPLIN, INC.

		
	By:	 	/s/ Thomas Wiggans
		 	Name: Thomas Wiggans
		 	Title: Chief Executive Officer

					
	INVENTORS:
		
		 	 GBS VENTURE PARTNERS PTY LTD
 (54
072 515 247) AS TRUSTEE FOR GBS BIOVENTURES IV

			
		 	By:	 	/s/ Geoff Brooke
		 		 	Name: Geoff Brooke
		 		 	Title: Managing Director

					
	MPM BIOVENTURES IV-QP, L.P.
	
	 By: MPM BIOVENTURES IV GP LLC, its General Partner
 By: MPM BIOVENTURES IV LLC, its Managing Member

			
		 	Name:	 	/s/ James Scopa
		 	Title:	 	Member
	
	MPM BIOVENTURES IV GMBH & CO. BETEILIGUNGS KG
	
	 By: MPM BIOVENTURES IV GP LLC, in its capacity as the Managing Limited Partner
 By: MPM BIOVENTURES IV LLC, its Managing Member

			
		 	Name:	 	/s/ James Scopa
		 	Title:	 	Member
	
	MPM ASSET MANAGEMENT INVESTORS BV4 LLC
	
	By: MPM BIOVENTURES IV LLC, its Manager
			
		 	Name:	 	/s/ James Scopa
		 	Title:	 	Member

					
	NEW ENTERPRISE ASSOCIATES 12, LIMITED PARTNERSHIP 
	
	 By: NEA Partners 12, Limited Partnership, its general partner
 By: NEA 12 GP, LLC, its general partner

			
		 	Name:	 	/s/ Charles W. Newhall, III
		 	Title:	 	Managing Member

					
	ORBIS MIS-ORBIS AUSTRALIA EQUITY FUND
	
	By: its Investment Manager, Orbis Investment Management (Australia) Pty Ltd.
			
		 	Name:	 	 /s/ Simon Marais

		 	Title:	 	 Director

  

					
	INTECH AUSTRALIAN SHARES HIGH ALPHA TRUST
	
	By: its Investment Manager, Orbis Investment Management (Australia) Pty Ltd.
			
		 	Name:	 	/s/ Simon Marais
		 	Title:	 	Director

  

					
	WARAKIRRI ENDEAVOUR FUND
	
	By: its Investment Manager, Orbis Investment Management (Australia) Pty Ltd.
			
		 	Name:	 	/s/ Simon Marais
		 	Title:	 	Director

  

					
	CONSTRUCTION AND BUILDING UNION SUPERANNUATION FUND
	
	By: its Investment Manager, Orbis Investment Management (Australia) Pty Ltd.
			
		 	Name:	 	/s/ Simon Marais
		 	Title:	 	Director

			
	ASIA UNION INVESTMENTS PTY LTD.
		
	By:	 	/s/ Chris Abbot
		 	Name: Chris Abbott
		 	Title: DirectorMaster Clinical Services Agreement

 Exhibit 10.30 
 

 
 MASTER SERVICES AGREEMENT 
  

 
 THIS CLINICAL MASTER SERVICES AGREEMENT (the
“Agreement”) is entered into as of the effective date, March 6, 2008 (“Effective Date”), by and between TKL Research, Inc., whose offices are located at 365 W. Passaic Street, Rochelle Park, NJ 07662 (together with its,
agents and/or affiliates, “TKL”), and Peplin Operations Pty Ltd. located at Level 2, 1 Breakfast Creek Rd, Newstead, Queensland 4006, Australia (“Sponsor”). 
 WHEREAS, Sponsor is engaged in development and commercialization of pharmaceutical products; 
 WHEREAS, TKL is a contract clinical research
organization with experience and expertise in planning, overseeing, and monitoring human clinical trials, as well as other related services; and 
 WHEREAS, Sponsor
desires to engage TKL to provide certain clinical trial services, and TKL desires to provide such services to Sponsor, subject to the terms and conditions of this Agreement. 
 NOW THEREFORE, in consideration of the foregoing and the mutual representations, warranties and covenants contained in this Agreement and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged,
the parties hereto hereby agree as follows: 
 1. MASTER AGREEMENT; SCOPE OF WORK 
 The terms and conditions of this Agreement shall govern the performance of services, including but not limited to services pertaining to clinical trials, by TKL for Sponsor under any individual scope of work document (each a “Scope of
Work”) entered into between TKL and Sponsor. Each Scope of Work shall be numbered in accordance with the number of the related protocol (each, a “Protocol”) and clinical trial (each, a “Clinical Trial”) to which it applies.
Each Scope of Work, when signed by each party, shall be deemed to form an integral part of this Agreement and shall be incorporated herein by this reference. If the Scope of Work is not explicitly related to a Clinical Trial, it shall be identified
by a unique Protocol name. 
 Each Scope of Work shall include a copy of the applicable Protocol, a detailed description of the services to be performed by TKL, a
timeline for performance, payment terms and any other applicable terms. This Agreement together with a particular Scope of Work (including any mutually agreed changes thereto) shall constitute the entire agreement for a particular Clinical Trial and
the execution of a Scope of Work and its attachment to this Agreement will authorize the performance of the services described in the “Services” section of the Scope of Work (“Services”). To the extent that any term or condition
of a Scope of Work conflicts with the terms and conditions of this Agreement, the terms and conditions of this Agreement shall control, unless the Scope of Work specifically states that the Scope of Work shall control over this Agreement.

 2. CLINICAL TRIAL ACTIVITIES 
 In addition to any obligations of the
parties set forth in the applicable Scope of Work or Protocol, the parties shall have the following general obligations with respect to each Clinical Trial: 
  
 ****Certain confidential information contained in this document, marked with four asterisks, has been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 1 

 

 
 2.1 Services 
 TKL shall conduct its
obligations concerning a Clinical Trial and the Services in accordance with the terms and conditions of this Agreement, the applicable Scope of Work, the applicable Protocol (as may be amended from time to time by Sponsor), the written instructions
of the Sponsor, the standard of care customary in the contract research organization industry, and the Applicable Standards (as defined in Section 5.2 hereof) (“Applicable Law”). TKL shall ensure that all of its employees and agents
furnishing Services hereunder comply with this Section 2.1 and all other relevant provisions of this Agreement. 
 2.2 Regulatory Matters 
 Sponsor shall be the regulatory sponsor of each Clinical Trial under Applicable Standards (as defined in Section 5.2) and, as may be required, will hold any clinical trial
approvals obtained from those regulatory authorities. Sponsor shall be responsible for all written and oral contact with all appropriate regulatory authorities, including but not limited to FDA, with the assistance of TKL, including, but not limited
to safety reports and annual reports required to be submitted by Sponsor to any such regulatory agency. TKL shall promptly provide to Sponsor all information, and execute all documents, requested by Sponsor that are necessary for the transfer by
Sponsor, as the regulatory sponsor, to TKL of certain obligations, as specified in the applicable Scope of Work, under FDA regulations, including without limitation 21 CFR § 312.52 “Transfer of Obligations to a Contract Research
Organization” and all information necessary to allow Sponsor to meet any regulatory obligation that remains with Sponsor as relates to such Scope of the Work. In addition, and without limitation on the foregoing, TKL will ensure that all
relevant requirements are met with respect to: (a) obtaining informed consent in accordance with 21 C.F.R. Part 50, as amended, and authorizations to release PHI (as defined in Section 2.10); (b) obtaining both initial and continuing
IRB and/or IEC review and approval in accordance with 21 C.F.R. Part 56, as amended; (c) obtaining and providing to Sponsor a fully completed and signed Form FDA 1572 and any other information required by 21 C.F.R. §312.53(c), as amended;
and (d) using all reasonable means to ensure that each Clinical Trial Investigator abides by the Clinical Trial-related commitments and obligations he or she undertook by signing Form FDA 1572. 
 Notwithstanding anything contained in this Agreement to the contrary, TKL shall not initiate or participate in any communications with any regulatory authorities concerning the
subject matter hereof, any Scope of Work, or any Clinical Trial contemplated hereby unless required by the Applicable Standards or requested to do so by Sponsor in writing, and then only after prior consultation with Sponsor. 
 2.3 Clinical Sites; Investigators 
 Prior to the commencement of a Clinical Trial, TKL
shall provide Sponsor for its review and approval a list of proposed clinical sites and investigators to perform the Clinical Trial, selected by TKL (in consultation with Sponsor) based on the expertise of the investigators in the therapeutic area
covered by the Clinical Trial and the ability of the clinical sites and investigators to recruit the required patient population for rapid enrollment in the Clinical Trial. TKL shall review FDA’s listings of debarred, disqualified and
restricted investigators and clinical sites, and shall not propose any clinical sites or investigators appearing in such listings. At Sponsor’s request, TKL shall provide additional information and documentation on the clinical sites and
investigators proposed by TKL, and Sponsor may identify additional clinical sites and investigators for inclusion in the Clinical Trial. 
  
 ****Certain confidential information contained in this document, marked with four asterisks, has been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 2 

 

 
 Sponsor may also make visits to any clinical site for purposes of independently evaluating the acceptability of such clinical site and
assessing the recommended clinical investigators. Sponsor shall be entitled to accept or reject, in its sole and absolute discretion, a clinical site and/or clinical investigator for inclusion in the Clinical Trial. 
 Unless otherwise stated in the Scope of Work, TKL will negotiate with investigators, sub- investigators, and/or investigative sites (collectively, “Investigators”) to
conduct a Clinical Trial, in accordance with the terms and conditions of TKL’s standard confidentiality, non-disclosure agreement (“CDA”) form, clinical trial agreement (“CTA”) form, with the approval of the Sponsor. Sponsor
and TKL may modify the CDA and CTA forms, by mutual agreement, to meet country- specific requirements of locations where the Clinical Trial may be conducted, or may use other CDA, CTA and/or CIA forms as mutually agreed to by the parties. TKL will
be responsible for translating the CDA, CTA and/or CIA forms into local languages in side-by-side translations if necessary for the purpose of negotiating with Investigators, and will ensure the accuracy and completeness of any and all such
translations. If an Investigator requires any revisions to any provisions of the CDA and CTA forms, TKL will submit the proposed revisions to Sponsor, and Sponsor will promptly review, comment on and/or approve such revisions. TKL will be
responsible for compensating Investigators pursuant to the provisions of the applicable CTA . 
 2.4 Clinical Trial Product Supply and Shipment 
 TKL shall be responsible for coordinating communications with Sponsor and Sponsor-designated vendors, and the responsibility for the Clinical Trial product (“Product”)
supply and shipment to sites will be set forth in the applicable Scope of Work. The Product and all information related thereto will be considered Confidential Information under Section 4. TKL will use the Product only in connection with the
applicable Protocol and for no other purpose without the prior written consent of Sponsor. Notwithstanding the foregoing, TKL may provide quantities of the Product to regulatory authorities when required by Applicable Law; provided,
however, that any such delivery is solely for this limited purpose and with all the protections of confidentiality permitted by law. TKL will ensure that the Product is at all times handled, stored, and administered in full compliance with
Applicable Law. Any unused or expired quantities of the Product remaining in the possession of TKL or any Investigators upon expiration or earlier termination of the applicable Scope of Work shall, at Sponsor’s direction and expense, be
promptly returned to Sponsor or its designee, or be disposed of in compliance with Applicable Law with written certification of same to Sponsor. 
 2.5 Clinical
Safety Reports 
 Immediately following the notification of occurrence of a “Serious Adverse Event,” as defined under Applicable Standards (as defined in
Section 5.2) and in the applicable Protocol relating to a Clinical Trial (but in no event more than 24 hours thereafter), TKL shall inform in writing Sponsor and/or any other body designated by Sponsor of such occurrence. At a minimum, Serious
Adverse Event reports shall include the patient’s initials/study identifier, the reporter’s name, and a description of the event and any other information required by the Protocol. Sponsor shall then prepare and provide to the appropriate
regulatory authorities all written safety reports and telephone reports within the timeframes and containing the information required under Applicable Standards (as defined in Section 5.2). TKL shall prepare all the documents required by the
clinical site’s IRB or other ethics committee for submission by the investigator in the occurrence of a Serious Adverse Event. 
  
 ****Certain confidential information contained in this document, marked with four asterisks, has been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 3 

 

 
 TKL shall prepare and submit to Sponsor all annual reports containing the description of such adverse events as required under
Applicable Standards (as defined in Section 5.2). Sponsor will provide TKL with a copy of each such report submitted to the regulatory authorities for distribution to the clinical site and from there to the IRB or other similar ethics, safety,
or medical committee. Sponsor and/or its designee may, at its option, communicate directly with any clinical site and investigator about any Serious Adverse Event or other adverse event. For the avoidance of doubt, Sponsor will remain responsible
for reporting of Serious Adverse Events as the named sponsor, but will discharge that responsibility with the assistance of TKL. 
 2.6 Changes or Modifications in
Scope of Work 
 (a)         Sponsor will have the right from time to time to review or request changes to the Scope of
Work pertaining to a particular Clinical Trial and/or Protocol, including but not limited to changes related to: 
  

	 	•	 	 The Protocol 

	 	•	 	 Case Report Forms (CRFs) 

	 	•	 	 Safety reporting 

	 	•	 	 Monitoring guidelines 

	 	•	 	 Quality assurance guidelines 

	 	•	 	 Data validation guidelines 

	 	•	 	 Final study report format 

 Any material alteration, modification or
amendment to the Clinical Trial requested by Sponsor or TKL shall be made in a written notice to the other party as a “Change Order” to the Scope of Work. Each Change Order shall explain in detail the specific changes to the Clinical
Trial, Protocol, Services, task, responsibility, duty, and/or timeline, as requested by Sponsor. Any Change Order submitted by Sponsor shall be approved in writing by TKL within 30 days. Sponsor shall have the right to approve or reject, within 30
days, a Change Order submitted to Sponsor by TKL. Sponsor reserves the right to remove services from the Services by notifying TKL, in writing, prior to TKL’s initiation of such services, subject to Sponsor’s payment obligations performed
by TKL up to the date of notice and any other payment obligations as contemplated by Section 3 generally. In no event will Sponsor be obligated to pay for such removed services. 
 An alteration, modification or amendment to a Clinical Trial shall be deemed to be “material” 1) by mutual agreement between Sponsor and TKL; or, 2) if such alteration, modification or amendment would, either
individually or in the aggregate (taking into account any prior alterations, modifications or amendments in connection with such Clinical Trial not previously included in a Change Order), result in a greater than ten thousand dollar ($10,000.00)
increase in a line item to the Budget Summary, attached hereto as Exhibit B. 
 Changes in the Budget Agreement in amounts up to but not exceeding ten thousand dollars
($10,000.00) can occur with prior written approval by the Sponsor (e.g., approval by electronic mail) but without the requirement for amendment to the Scope of Work, provided that specific details for Internal Costs (as set forth in Exhibit B) and
documentation for Pass Through Expenses are presented to the SPONSOR prior to TKL’s commencement of such services and TKL provides to Sponsor with itemized invoices for such expenses. Specific details for changes to Internal Costs include
TKL’s timesheet system which may be audited at the Sponsor’s discretion with reasonable notice to TKL. 
  
 ****Certain confidential information contained in this document, marked with four asterisks, has been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 4 

 

 
 (b)         Promptly following receipt of a Change Order, TKL and Sponsor shall discuss and set
forth in writing in the Change Order any impact of the changes requested in the Change Order on the fees payable for (whether an increase or decrease) or other conditions of the Clinical Trial. Upon the parties’ mutual agreement concerning the
terms of the Change Order and execution of the Change Order, such Change Order will be effective and its terms shall be incorporated in the applicable Scope of Work and the parties shall amend the applicable Scope of Work in accordance with
Section 8.2 hereof (“Approved Change Order”). 
 (c)         Sponsor and TKL agree that certain costs for
activities not meeting the requirements of “material change” may not be charged if they were caused by TKL’s non-compliance with any aspect of this agreement. 
 2.7 Records; Sponsor’s Right to Audit 
 (a)         As part of its services hereunder, TKL shall maintain
complete and accurate records, accounts, notes, reports and data pertaining to any Clinical Trial and TKL’s activities hereunder and under any applicable Scope of Work and in accordance with Applicable Law (“Service Records”). Service
Records shall be deemed to be Confidential Information under Section 4.1 hereunder. Sponsor may at its option, upon reasonable advance notice and during normal business hours, inspect and audit all information, databases and records, accounts,
notes, reports, and data pertaining to any Clinical Trial and TKL’s performance under this Agreement or under any applicable Scope of Work, and shall be permitted to make copies thereof and to observe the conduct of any Clinical Trial. During
the term of this Agreement (or the term of any Scope of Work that extends beyond the term of this Agreement) and for any longer period specified in any Scope of Work or required by the Applicable Standards, TKL shall maintain all materials,
information, databases and records, accounts, notes, reports, and data obtained or generated by TKL in the course of providing services under this Agreement, including all computerized records and files, in a non-public and secure area in accordance
with TKL’s archiving policy and Applicable Law. Sponsor may at any time have access to any and all clinical data for any Clinical Trial (and shall be permitted to make copies thereof) and clinical sites. 
 (b)         At Sponsor’s written request, TKL shall cooperate with any regulatory authorities and allow them access to applicable
records and data. TKL shall promptly inform Sponsor of any request or effort by any regulatory authority to review records and data, or to contact, visit, or inspect TKL’s (or any Investigator’s) records and data, relating to any Clinical
Trial or TKL’s (or such Investigator’s) performance of services under this Agreement or any Scope of Work, and shall notify Sponsor immediately (and in no event later within 1 business day) if any regulatory authority issues or gives to
TKL (or any such Investigator) any notice of intent to inspect, notice of inspection, notice of inspectional observations, warning letter, or other written communication concerning any Clinical Trial, and TKL immediately (and in no event later than
within 1 business day) shall provide Sponsor copies thereof. Sponsor shall have the opportunity to review, revise, and/or approve of any response prior to submission of a response by TKL to any governmental regulatory authority submitted by TKL
during the course of the inspection. 
 2.8 Periodic Reports; Return of Materials 
 (a)         TKL shall provide written reports to Sponsor, from time to time as specified by any Scope of Work, concerning the status and results of the Services to date under any applicable Scope of
Work (each a “Progress Report”). TKL will furnish Sponsor with a final report including all findings, data, documents and other information specified by or required under the Scope of 
  
 ****Certain confidential information contained in this document, marked with four asterisks, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 5 

 

 
 Work (“Final Report”). All information provided by TKL to Sponsor hereunder with regard to Clinical Trial participants will be
furnished by TKL without any subject identifiable information. 
 (b)         At the expiration or termination of any Scope of
Work, all Service Records and other materials, information, databases and records, accounts, notes, reports and data obtained or generated by TKL in the course of providing services under such Scope of Work shall, at Sponsor’s option and at its
direction and written request, be (i) returned and delivered to Sponsor or to any third party designated in writing by Sponsor at its offices as Sponsor shall request, (ii) retained by TKL under a mutually agreeable arrangement, or
(iii) destroyed. In no event will TKL dispose of materials, information, databases and records, accounts, notes, reports or data obtained or generated by TKL in the course of providing services under any applicable Scope of Work without first
giving Sponsor one hundred twenty (120) days’ prior written notice of its intent to do so and complying with any directions or written requests provided by Sponsor during such one hundred twenty (120) day period. 
 2.9 Enrollment of Subjects. 
 TKL will not commence enrollment of volunteer subjects in a
Clinical Trial unless and until TKL (a) has been notified by Sponsor that all approval, authorizations, and documentation necessary to conduct the Clinical Trial have been obtained (whether or not the applicable Scope of Work requires TKL to
obtain such approvals, authorizations and documentation in a particular country or jurisdiction in which the Clinical Trial will be conducted), and (b) TKL has acknowledged receipt of the Protocol for the Clinical Trial thereby agreeing to
perform its responsibilities detailed herein. TKL shall, where required by Applicable Law and/or the applicable Protocol, submit the Protocol for review and approval to any applicable regulatory authorities, Institutional Review Boards
(“IRBs”), Ethic Research Boards (“ERBs”) or Independent Ethics Committees (“IECs”). Sponsor may close enrollment of subjects in a Clinical Trial upon written notice to TKL. 
 2.10 Protected Health Information. 
 TKL and Sponsor recognize that certain information
relating to subjects participating in a Clinical Trial may be considered Protected Health Information (“PHI”) and protected under HIPAA (as defined in Section 5.2) and its implementing regulations, and may also be protected under
other applicable laws, including, without limitation, the European Data Protection Legislation. TKL will take all reasonable measures to ensure that all authorizations required under HIPAA, the European Data Protection Legislation and other laws are
obtained from subjects at any site under the Clinical Trial, permitting TKL to disclose such participants’ PHI to Sponsor as contemplated by this Agreement and the applicable Protocol. Sponsor may further disclose such PHI to the extent
permitted under this Agreement, the applicable Protocol, HIPAA, the European Data Protection Legislation and other applicable law. 
 2.11 Cooperation with CROs.

 TKL acknowledges that Sponsor, without the consent of TKL, has designated or may designate one or more other third-party contract research organizations to
assist the Sponsor outside the United States (“CROs”) to assist Sponsor with any Clinical Trial, and TKL agrees to reasonably cooperate with any and all CROs or other designees of Sponsor in the performance of the Services hereunder.
Notwithstanding the foregoing, TKL will not contact or otherwise interact with the CROs in performing the Services unless specifically authorized by Sponsor in connection with TKL’s performance of the Services. Any conclusion reached by TKL
regarding 
  
 ****Certain confidential information contained in this document, marked
with four asterisks, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 6 

 

 
 data quality or the performance of services by such CROs will be conveyed solely to Sponsor. Sponsor will have sole responsibly for
communicating with the either of the CROs regarding any such conclusion or the services rendered by the CROs in connection with the Clinical Trial. Sponsor will be responsible for the integrity of any data or information from such third party CROs
to the extent the same is incorporated into the data base developed in connection with the Study conducted by TKL, unless TKL’s independent analysis and interpretation by TKL of such third party CRO data and information is specifically
authorized in writing by Sponsor to TKL as a Change Order. 
 3. COMPENSATION; PAYMENTS 
 3.1 Compensation 
 As payment to TKL for Services provided by TKL under any applicable Scope of Work (Exhibit A), Sponsor shall
compensate TKL in accordance with the terms set forth in such Scope of Work, as the same may be amended by mutual written consent of the parties hereto (the “Fees”). The parties acknowledge and agree that the total costs for Services
performed and, if authorized by Sponsor, reimbursable out-of-pocket expenses or project pass-through costs actually incurred with respect to a particular Scope of Work will not exceed the figure for total project costs specified in such Scope of
Work without the prior written consent of Sponsor and/or execution of an Approved Change Order under Section 2.6(b) of this Agreement, except as provided otherwise in Section 2.6(a). In the event of a change in any material Clinical Trial
parameter, such as number of subjects, number of Clinical Trial sites, Clinical Trial timeline or Protocol design, results in an increase or decrease in the scope or amount of Services for reasons outside the reasonable control of TKL, such changes
and their financial implications will be promptly summarized in writing by TKL and provided to Sponsor. Any additional Services (and associated budget increases) must be mutually approved by the parties in writing, prior to the performance of such
Services and the applicable Scope of Work amended accordingly. The parties agree that they shall in good faith negotiate the reasonable costs of the additional Services, and TKL shall use its best efforts to mitigate the impact of such additional
Services on the budget for the Clinical Trial. 
 In the event that a Clinical Trial or part thereof is terminated before completion, the applicable Scope of Work
shall be amended, as Sponsor directs in writing, to reflect the impact of such termination and TKL will be compensated 1) for all work actually and satisfactorily completed to date; 2) for all uncancellable obligations as of the effective date of
termination with regard to third parties who are providing goods and/or services that were approved by Sponsor and that reasonably fall within the work outlined in the applicable Scope of Work (“Non-Cancelable Costs”) (provided that TKL
shall use its best efforts to mitigate any such obligations), solely to the extent such Services have not already been paid for by Sponsor and 3) for 60 days of Project Management labor and the labor portion of Clinical Monitoring for staff
non-allocatable to other projects. In addition, TKL will promptly reimburse Sponsor for any amounts paid by Sponsor pursuant to this Agreement for Services that have not yet been completed (other than Non-Cancelable Costs) as of the effective date
of such termination. The foregoing obligations of Sponsor to compensate TKL in the event of termination before completion shall not apply in the event that termination by Sponsor resulted from a material breach of contract by TKL. Project Management
costs will be determined based on the 1-month period following the time point at which the study was terminated using the Project Management Allocation spreadsheet (Exhibit D). Clinical Monitoring costs will be based on projected monitoring visits
during the 1-month period following termination as identified in the Scope of Work. However, since it is in the best interest of TKL and its employees to remain continuously engaged in the conduct of 
  
 ****Certain confidential information contained in this document, marked with four asterisks, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 7 

 

 
 their normal professional duties and for TKL to replace the income stream lost as a result of the study cancellation, TKL will make
every effort to re-allocate Project Management and Clinical Monitoring personnel to replacement activities. Therefore, the Sponsor will only be charged for inactive hours for which replacement activities can not be found during said time.

 In the event of a suspension or material delay(s), Sponsor and TKL agree that a delay in a Clinical Trial of thirty (30) or more days, cumulatively or
sequentially, shall constitute a condition of additional reimbursement provided that delay is not caused by TKL (unless or until Sponsor terminates such Clinical Trial) and the parties shall amend the Scope of Work with the execution of a Change
Order. 
 Any funds held by TKL that are unearned at the conclusion of the termination process shall be returned to Sponsor within thirty (30) days of termination
of the applicable Scope of Work. 
 3.2 Pass-through Expenses 
 To the extent
that the Fees set forth in an applicable Scope of Work for a Clinical Trial provide that TKL will pass through certain expenses (“Pass Through Expenses”) of a Clinical Trial to Sponsor, reimbursement by Sponsor for such pass-through
expenses (including any increase in Pass Through Expenses) is subject to Sponsor’s prior written approval of such expenses and the provision by TKL of reasonable documentation attesting to such payments being made. 
 Compensation in the event of delays or termination is addressed in Section 7.4. 
 3.3
Payments; Taxes 
 All payments provided for under the terms of any Scope of Work shall be invoiced to Sponsor. Sponsor shall make payments on any undisputed
amounts within thirty (30) calendar days of the date of receipt of the invoice. Notwithstanding anything to the contrary herein, in the event Sponsor in good faith disputes any invoice or portion thereof, Sponsor with notify TKL, and payment
for such invoice or portion there of will not be due until the parties resolve such dispute, provided that Sponsor will promptly pay the undisputed portion of any disputed portion of any disputed invoice. Taxes (including any penalties thereon)
imposed on any payment made to TKL pursuant to an applicable Scope of Work shall be the sole responsibility of TKL. 
 3.4 Audit 
 During the term of this Agreement (or the term of any Scope of Work that extends beyond the term of this Agreement) and for a period of two (2) years thereafter, Sponsor
(and/or its consultants or other agents) shall have the right to audit TKL’s records, agreements and other documents in a manner sufficient to permit Sponsor to audit the services actually performed by TKL against the agreed-upon Fees, as well
as calculation and recording of fees. Any such audit shall take place at a time and place agreed to by the parties no later than ten (10) days following Sponsor’s notice of exercise of its audit rights hereunder (unless a later date is
mutually agreed to by the parties). TKL shall cooperate fully in any audit conducted hereunder and shall provide reasonable access to relevant employees, agents, and other representatives of TKL and to TKL’s books, records, agreements, and
other documents as Sponsor reasonably requests. Sponsor shall be responsible for its own expenses for these audits, including the costs of any third-party accountants and consultants; provided, however, that in the event that audit results determine
that any fees have been overstated for the period examined, TKL shall pay all 
  
 ****Certain confidential information contained in this document, marked with four asterisks, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as
amended. 
  

 8 

 

 
 reasonable costs and expenses incurred by Sponsor in the course of making such determination, including the fees and expenses of such
third-party accountants and consultants. 
 4. CONFIDENTIALITY AND PROPRIETARY RIGHTS 
 4.1 Confidentiality 
 TKL agrees to maintain as confidential any and all materials, data and information, trade secrets or know how
relating to this Agreement, any Scope of Work, Clinical Trial, Product or Protocol, as well as all regulatory documentation, project management plans, feasibility studies, reports Services Records and Inventions that TKL has received or receives
from Sponsor or its designees or agents, or obtains as a result of the performance by TKL of services under this Agreement, through oral, electronic, graphic or other tangible or intangible means, whether or not marked ‘confidential’ or
‘proprietary’ or that TKL generates, prepares, or otherwise obtains as a result of performing the Services under this Agreement (collectively, “Confidential Information”), and further agrees to disclose the Confidential
Information only to those persons under TKL’s direct control or designated sub-contractors who have a need to know the Confidential Information for purposes of performing TKL’s obligations under this Agreement and who have agreed in
advance in writing to comply with and be bound by the terms of this Section 4. All Confidential Information containing personal data will be handled in accordance with all Applicable Law, including without limitation HIPAA. 
 At no time shall TKL use, or allow others to use, the Confidential Information for any purpose other than performance of TKL’s obligations under and in accordance with this
Agreement or disclose the Confidential Information to any third party without the prior written consent of Sponsor and then only after the party to whom such disclosure will be made has agreed in writing to comply with and be bound by the terms of
this Section 4. The foregoing confidentiality obligations shall not apply to Confidential Information to the extent TKL can establish by competent documentary proof that: 
 (a)         such Confidential Information was already properly and independently known to TKL at the time of disclosure to TKL, as shown by prior written records, provided that TKL
advises Sponsor promptly upon discovering that such Confidential Information was already known to TKL; 
 (b)         such
Confidential Information was generally available to the public or otherwise part of the public domain at the time of disclosure to TKL; 
 (c)         such Confidential Information became generally available to the public or otherwise part of the public domain after its disclosure or development, as the case may be, and other than
through an act or omission of TKL (or its employees, agents, subcontractors, advisors or other personnel under TKL’s control); 
 (d)         such Confidential Information was properly disclosed to TKL by a third party who had no obligation not to disclose such information to others; or 
 (e)         TKL was required to disclose such information pursuant to Applicable Standards, provided that TKL notified Sponsor in writing
at least ten (10) days in advance to provide Sponsor with the opportunity to seek an appropriate protective order to prevent such disclosure or to allow for the parties to attempt in good faith to agree upon a mutually satisfactory way to

  
 ****Certain confidential information contained in this document, marked with four
asterisks, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 9 

 

 
 disclose such Confidential Information as necessary for this limited purpose and with all protections of the confidentiality permitted
by law. 
 TKL agrees that upon the expiration or earlier termination of this Agreement or, at Sponsor’s written request, it will (and will cause its directors,
officers, employees, agents, representatives, advisors and subcontractors to) return to Sponsor all parts of its Confidential Information provided by it in documentary or electronic form and return or destroy any copies thereof made by its
directors, officers, employees, agents, representatives or subcontractors. Notwithstanding the foregoing, TKL may maintain, in a secure area, one (1) copy of any and all Confidential Information that TKL is required to maintain under Applicable
Laws. 
 TKL acknowledges that disclosure or distribution of Confidential Information, or the use of Confidential Information contrary to the terms of this Agreement,
may cause irreparable harm for which damages at law may not be an adequate remedy, and agrees that the provisions of this Agreement prohibiting disclosure or distribution of Confidential Information or use contrary to the provisions hereof may be
specifically enforced by a court of competent jurisdiction in addition to any and all other remedies available at law or in equity. 
 4.2 Publication

 TKL shall not publish any articles or papers or make any presentations, nor assist any other person in publishing any articles or papers or making any
presentations, relating or referring to this Agreement, any Scope of Work, Clinical Trial or Protocol, the services performed by TKL hereunder, Clinical Trial results, any Product, or data, information, materials obtained or generated in the
performance of TKL’s obligations hereunder, in whole or in part, without the prior written consent of Sponsor which consent may be withheld in its sole discretion. 
 4.3 Proprietary Rights 
 (a)         Neither anything contained in this Agreement (or in any applicable Scope
of Work) nor the disclosure or provision to TKL of any Confidential Information or other information or items shall be deemed to transfer or grant to TKL, or any other person or entity any right, title, interest, or license in, to or under any
patent or patent application owned or licensed by Sponsor or other intellectual property or other right of Sponsor or in or to any information, discoveries, knowledge, experience, processes, procedures, devices, compositions of matter, skills,
know-how, samples, trade secrets, designs, formulae, specifications, methods, techniques, compilations, programs, devices, technical information, concepts, developments, inventions or improvements, whether patentable or not, or other technology,
inventions or property of Sponsor. 
 (b)         TKL agrees that the intellectual property and materials that are the subject
of this Agreement or any Scope of Work hereunder, including without limitation all information, discoveries, knowledge, experience,-processes, procedures, devices, compositions of matter, skills, know-how, samples, trade secrets, designs, formulae,
specifications, methods, techniques, compilations, programs, devices, technical information, concepts, developments, inventions or improvements, whether patentable or not, and materials related to any Product, Clinical Trial or Protocol, or
otherwise derived as a direct or indirect result of the Services, whether generated by Sponsor, TKL, any Investigators or their employees or agents, either solely or jointly with others (“Inventions”), shall promptly be made known to
Sponsor in writing and Sponsor shall have sole and exclusive rights to all such Inventions, which shall be the sole and exclusive property of Sponsor, provided, that Inventions related to computer software programs, statistical methodologies,
technical processes, methods, formulae or analyses 
  
 ****Certain confidential
information contained in this document, marked with four asterisks, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 10 

 

 
 developed by TKL prior to the date of this Agreement or during the term of this Agreement that relate solely to conducting clinical
trials and not to the development activities of Sponsor and that can be used by TKL without disclosing or incorporating any Inventions or Confidential Information (the “TKL Property”), as shown by prior written records, shall remain the
sole and separate property of TKL; provided that, TKL agrees to disclose any TKL Property or improvements to TKL Property made in the course of fulfilling its obligations under this Agreement (“TKL Property Improvements”) and hereby grants
Sponsor a worldwide, fully paid, royalty-free, perpetual, irrevocable right and license, with the right to sublicense to use such TKL Property Improvements for development and manufacture of any Product pursuant to this Agreement, on an
non-exclusive basis. TKL agrees that it will cause clinical sites and investigators to execute agreements in favor of Sponsor providing Sponsor with the same intellectual property rights to Inventions arising out of the Clinical Trial performed by
such investigators at such clinical sites. All Inventions will be deemed to be Confidential Information subject to the provisions of Section 4.1. 
 (c)         Subject to the provisions of Sections (a) and (b) above, TKL hereby agrees to assign, and hereby assigns to Sponsor, without additional compensation, its entire right, title and
interest, present and future, in and to all Inventions. To the extent, if any, that any Inventions are not assignable, TKL (i) unconditionally and irrevocably waives the enforcement of such rights, and all claims and causes of action of any
kind against Sponsor with respect to such rights; (ii) agrees, at Sponsor’s request and Sponsor’s expense, to consent to undertake or join in any action to enforce such rights; and (iii) hereby grants to Sponsor a perpetual,
irrevocable, fully paid-up, royalty-free, transferable, sub-licensable (through multiple levels of sublicenses), exclusive, worldwide right and license to use, reproduce, distribute, display and perform (whether publicly or otherwise), prepare
derivative works of and otherwise modify, make, sell, offer to sell, import and otherwise use and exploit (and have others exercise such rights on behalf of Sponsor) all or any portion of such Invention, in any form or media (now known or later
developed). 
 (d)         Whenever requested to do so by Sponsor, TKL will execute any and all applications, assignments, or
other instruments and give testimony which Sponsor shall deem necessary to apply for and obtain patent rights anywhere in the world; or to otherwise protect the interests of Sponsor therein. Sponsor shall reasonably compensate TKL, subcontractors
and agents for the time actually devoted to said activities and reimburse TKL for reasonable expenses actually incurred. These obligations shall continue beyond the termination of this Agreement with respect to Inventions, and shall be binding upon
assignees, administrators and other legal representatives of TKL. 
 (e)         Neither TKL nor any Investigator, clinical
site employee, agent, or other representative of TKL shall file, directly or indirectly, in its own name or in the name of third parties, any application for patent rights or any other right of intellectual property protecting or mentioning any part
of the Inventions or Confidential Information or any process pertaining to the use of the Inventions or Confidential Information. 
 4.4 Rights in Materials, Data
and Reports 
 TKL hereby assigns, and shall cause all Investigators to assign, to Sponsor all right, title and interest, including copyrights and other
intellectual property rights, in and to all Inventions, including without limitation, works of authorship, data, reports and other materials, including without limitation protocols, investigators’ brochures, case report forms and summary
statistical reports, which shall be developed in performance of the Clinical Trial or by TKL in the course of 
  
 ****Certain confidential information contained in this document, marked with four asterisks, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of
1933, as amended. 
  

 11 

 

 
 performing its obligations under this Agreement. For avoidance of doubt, the obligations of TKL to assign and deliver to Sponsor the
subject matter hereunder shall remain in effect notwithstanding any dispute between the parties. Furthermore, for the avoidance of doubt, this clause shall not apply to any TKL Property or any direct developments of such TKL Property that may occur
during the term of this Agreement. 
 5. ADDITIONAL REPRESENTATIONS, WARRANTIES AND COVENANTS 
 TKL represents, warrants and covenants that: 
 5.1 Conduct of Activities 
 TKL will perform, and cause all Investigators to perform, the Services and obligations to be performed by TKL or an Investigator pursuant to this Agreement and any applicable Scope of Work in a competent and professional manner
in conformance with the standard of care usually and reasonably expected in the performance of such activities in the pharmaceutical industry, and in each case in conformance with procedures approved in advance by Sponsor and to its reasonable
satisfaction. TKL and its personnel performing Services have, and will maintain through the performance of the Services, all material information, licenses, approvals or certification necessary for safety, adequately and lawfully performing the
Services. If any license, approval or certification is suspended or revoked during the term of the Agreement, TKL will notify Sponsor within twenty- four (24) hours in writing. 
 5.2 Compliance 
 TKL will perform, and cause all Investigators to perform, the Services and obligations to be performed by TKL or an
Investigator pursuant to this Agreement and any applicable Scope of Work in compliance with all applicable national, multi-national, supranational, foreign, federal, state and local laws, rules, regulations, directives and published guidelines
relating to the conduct of the applicable Scope of Work and Clinical Trial and the use of investigational drugs in humans, and with the standard of care customary in the pharmaceutical industry, including but not limited to (i) the Health
Insurance Portability and Accountability Act of 1996, and the regulations promulgated pursuant thereto, including, but not limited to, 45 C.F.R. Part 160 and Part 164, Subparts A and E (Privacy Rule) and Subpart C (Security Rule)
(“HIPAA”), (ii) the ICH Consolidated Guidance for Good Clinical Practice (April 1996), (iii) the United States Federal Food, Drug and Cosmetic Act and the regulations promulgated pursuant thereto, (iv) the World Medical
Association Declaration of Helsinki; (v) the Directive EC/95/46 of the European Parliament and of the Council, and any applicable national legislations promulgated thereunder and any and all laws and regulations applicable in the countries in
which such data collection and processing would occur (“European Data Protection Legislation”); (vi) the 2001/20/EC Directive relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal
products for human use and any legislation enacted thereunder and (vii) other local laws, rules, regulations and guidelines set forth in a Scope of Work and (the foregoing, collectively, the “Applicable Standards”). TKL will promptly
notify Sponsor of any observed or suspected violations of such Applicable Standards by itself or by any investigators and clinical sites. 
 5.3 No Debarment/ No
Proceedings 
 In accordance with the requirements of the U.S. Food, Drug, and Cosmetic Act, as amended, TKL certifies that it is not and will not utilize the
services of any person or affiliate 
  
 ****Certain confidential information contained in
this document, marked with four asterisks, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 12 

 

 
 person/organization debarred under 21 U.S.C.§ 335a in any capacity in connection with the performance of the Services provided
under this Agreement or any Scope of Work. TKL also certifies that it is not and will not utilize the services of any person or affiliate person/organization for whom convictions subject to debarment have occurred in the past five (5) years in
any capacity. If at any time after execution of this Agreement, TKL becomes aware that it or any person employed by it or any affiliate person/organization, including any consultant or sub-contractor whose services TKL has utilized or will utilized
with respect to the services to be performed hereunder, has been or is in the process of being debarred or is convicted of an offence subjecting it or any person to debarment, TKL will so notify Sponsor at once. TKL shall regularly, but no less
frequently than once per calendar quarter, review the names of (a) those persons whose services it utilizes, whether or not employed by TKL, and (b) the Investigators retained for any Clinical Trial against the list of debarred individuals
or organizations. As of the date of execution of this Agreement, no claims actions, proceedings or investigations that might result in such restrictions, exclusions, sanctions or other disciplinary measures are pending or, to the best of TKL’s
knowledge, threatened against TKL or any of its personnel who provide Services thereunder and TKL will immediately notify Sponsor of any allegations or investigations of TKL personnel regarding actual or threatened claims of professional or research
misconduct or any violation of law relating to or potentially affecting Sponsor, this Agreement, any Clinical Trial or Scope of Work, or the performance of the Services. 
 6. INDEMNIFICATION; INSURANCE 
 6.1 Indemnification by TKL 
 TKL agrees to defend, indemnify, and hold harmless Sponsor and its affiliates, and their respective employees, officers, directors, and consultants against and from any losses, claims, liabilities, damages, proceedings, or investigations
(including reasonable attorney fees and court costs) (collectively, “Losses”) arising out of or in connection with (i) any TKL lndemnitee’s (as defined in Section 6.2) negligence or intentional misconduct; or (ii) a
breach of any covenant, warranty or representation in or any obligations under this Agreement or any Scope of Work by any TKL Indemnitee; or (iii) a violation by any TKL lndemnitee of Applicable Law, provided that: 
 (a)         such indemnification shall be limited to the extent such Losses arose out of Sponsor’s negligence, intentional misconduct
or breach of any covenant, warranty or representation in this Agreement or any Scope of Work; 
 (b)         that the Sponsor
lndemnitees notify TKL within a reasonable period after incurring such loss or receiving such claim and shall reasonably cooperate with TKL in its defense (such cooperation to be at TKL’s expense); and 
 (c)         TKL will have the right to select defense counsel reasonably acceptable to Sponsor and to direct the defense or settlement of
any such claim or suit. Notwithstanding the foregoing, the Sponsor will have the right to choose its own counsel and defend against any claim at its own expense, without prejudicing its right to seek indemnification from TKL as described herein;
provided, however, that Sponsor will make no admission to, or any settlement or agreement with, any person or party who is in any manner related to any claim, action or proceeding for which indemnification may be sought hereunder,
without the TKL’s prior written consent. 
  
 ****Certain confidential information
contained in this document, marked with four asterisks, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 13 

 

 
 6.2 Indemnification by Sponsor 
 Sponsor
agrees to defend, indemnify, and hold harmless TKL and its affiliates, and their respective employees, officers, directors, and approved consultants (the “TKL lndemnitees”) against and from any Losses brought against TKL lndemnitees, or
any one of them, by a third party arising out of or in connection with TKL’s performance of its obligations under this Agreement or any Scope of Work, provided that: 
 (a)         Sponsor will have no obligation hereunder to the extent that the Losses arose out of (i) any TKL lndemnitee’s negligence or intentional misconduct; or (ii) breach of any
covenant, warranty or representation in or any obligations under this Agreement or any Scope of Work by any TKL lndemnitee; or (iii) ) a violation by any TKL lndemnitee of Applicable Law; 
 (b)         that the TKL Indemnitees notify Sponsor within a reasonable period after receipt of such claim and cooperate with Sponsor in
their defense; and 
 (c)         Sponsor will have the right to select defense counsel (reasonably acceptable to TKL) and to
direct the defense or settlement of any such claim or suit. Notwithstanding the foregoing, the TKL will have the right to choose its own counsel and defend against any claim at its own expense, without prejudicing its right to seek indemnification
from Sponsor as described herein; provided, however, that TKL will make no admission to, or any settlement or agreement with, any person or party who is in any manner related to any claim, action or proceeding for which indemnification
may be sought hereunder, without the Sponsor’s prior written consent. 
 6.3 Limitation of Liability 
 With the exception of liability arising out of a party’s indemnification obligations hereunder or arising out of a breach of a party’s obligations under Section 4.1
(Confidentiality), neither party shall be liable for any indirect, incidental, special or consequential damages, including loss of profits, revenue, goodwill, shareholder confidence and similar remote damages (“Indirect Damages”) incurred
by the other party, whether in an action in contract or tort, even if it has been advised of the possibility of such damages; provided, however, that TKL may be liable for Indirect Damages not to exceed **** dollars ($****) for material breaches of
its proprietary rights obligations as set forth in Section 4.3 and in the case of TKL’s gross negligence or willful misconduct; provided however that this limitation of liability shall not apply to TKL’s material breach of its
confidentiality obligations as set forth in Section 4.1. 
 6.4 Insurance 
 Sponsor will carry Professional Liability and other applicable insurance policies during the term of this Agreement in such amounts and providing such coverage as is reasonable and customary for commercial entities undertaking the Clinical
Trials contemplated by this Agreement. Sponsor shall provide TKL with a copy of the clinical trial insurance policy. 
 TKL will assure that all Investigators carry
$****/$**** Professional Liability insurance or as per individual state limitations and will obtain copies of insurance certificates substantiating each Investigator’s coverage. TKL will carry Commercial General Liability insurance in the
amount of $****/$**** and Workers’ Compensation insurance during the term of this Agreement. 
  
 ****Certain confidential information contained in this document, marked with four asterisks, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as
amended. 
  

 14 

 

 
 7. TERM; TERMINATION; POSTPONEMENT 
 7.1
Term 
 This Agreement shall be effective as of the Effective Date, and shall continue for a period of five (5) years thereafter, unless earlier terminated as
set forth herein, or extended by written mutual agreement of the parties. The termination of this Agreement will automatically terminate any and all Scope of Work, unless otherwise agreed to by the parties in writing. The termination of any or all
Scope of Work will not automatically terminate this Agreement, unless otherwise agreed to by the parties in writing. 
 7.2 Termination for Patient Safety

 In the event Sponsor believes that patient safety considerations may indicate that any Clinical Trial or part thereof should cease, Sponsor shall promptly
consult with TKL regarding such belief and the reasons therefore, and TKL shall cooperate with Sponsor in making any changes necessary to address and cure such safety considerations. Sponsor may terminate the Clinical Trial immediately if Sponsor
determines that patient safety considerations require such termination. 
 7.3 Termination 
 This Agreement or any applicable Scope of Work may be terminated (i) immediately by Sponsor or TKL, as the case may be, upon the material breach of this Agreement or such Scope of Work by the other party and the failure of
such other party to cure such breach within thirty (30) days of receipt of the non-breaching party’s written notice of such breach, unless the Sponsor in its sole discretion determines that a breach by TKL of Applicable Law, this Agreement
or any Scope of Work cannot be cured, in which case TKL will not have the opportunity to cure and/or (ii) by Sponsor without cause upon written notice to TKL of its intent to terminate, and subject to the payment provisions set forth in
Section 3.1. 
 7.4 Effect of Termination, Suspension or Delay 
 Upon
termination of this Agreement or any applicable Scope of Work, TKL shall cooperate with Sponsor to provide for an orderly completion of the Services necessary for appropriate close-out including, to the extent relevant, an orderly transfer of
TKL’s responsibilities with respect to any Clinical Trial or part thereof to Sponsor or its designee, including without limitation, TKL’s assignment at Sponsor’s request of one or more clinical trial agreements with one or more
particular clinical trial sites to Sponsor, if applicable. 
 Upon receipt of written notice of termination, suspension or delay of the Clinical Trial or any part
thereof under a Scope of Work, TKL shall use its best efforts to immediately suspend its and each affected Investigator’s performance of services, shall make no further expenditures nor incur further expenses, shall attempt to mitigate any
expenses or costs already incurred in connection with the suspension or delay of services, except those directly caused by the termination, suspension or delay, under the Scope of Work with respect to the Clinical Trial. In the event of resumption
of the Clinical Trial or any part thereof, Sponsor shall notify TKL in writing, at which time TKL will resume, and instruct each clinical site to resume, their respective activities with respect to the Clinical Trial in accordance with the terms of
the applicable Scope of Work. 
  
 ****Certain confidential information contained in this
document, marked with four asterisks, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 15 

 

 
 Reference is made to Sections 2.6 and 3.1 regarding compensation to TKL as a result of a termination, suspension or delay. 

8. MISCELLANEOUS 
 8.1 Independent Contractors 
 For purposes of this Agreement, the parties agree that they are and will be acting solely as independent contractors and nothing contained in this Agreement is intended or shall
be construed to place them in the relationship of partners, principal and agent, employer/employee or joint ventures, nor to give either party the authority to legally bind the other party, and neither party shall hold itself out as having such
authority. 
 8.2 Amendments 
 This Agreement and any Scope of Work may not
be amended or modified in any manner except by an instrument in writing signed by both of the parties. 
 8.3 Entire Agreement 
 This Agreement (including each Scope of Work entered into hereunder) constitutes the entire agreement of the parties with respect to the subject matter hereof, and it supersedes
all prior oral and written agreements, commitments or understandings with respect to the matters provided for herein, including without limitation any memorandum of understanding, letter of intent or letter of agreement. 
 8.4 Governing Law 
 This Agreement and the performance hereof shall be governed,
interpreted, construed and regulated by the laws of the State of New Jersey. 
 8.5 Notices 
 All notices, demands, requests, or other communications which may be or are required to be given, served, or sent by any party to any other party pursuant to this Agreement or any Scope of Work shall be in writing and shall be
mailed by overnight courier, or transmitted by hand delivery or by facsimile, addressed as follows: 
 If to Sponsor:  
 David Smith 
 Company Secretary 
 Peplin 
 Level 2, 1 Breakfast Creek Rd 
 Newstead, QLD 4006

 Australia 
 Telephone: +617 3250 1200; Facsimile: +617 3250 1299 
  
 ****Certain confidential information contained in this document, marked with four asterisks, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 16 

 

 
 With a copy to: 
 Arthur Bertolino, MD, PhD

 Chief Medical Officer 
 Peplin 
 6475 Christie Avenue 
 Emeryville, CA 94608 
 Telephone: (510) 653-9700; Facsimile: (510)-653-9704 
 If to TKL: 
 TKL Research, Inc. 
 365 W. Passaic Street 
 Rochelle Park, NJ 07662 
 Attention: Robert C. Reardon, PhD - Executive Vice President 

Telephone: (201) 587-0500; Facsimile: 201-587-0209 
 Each party may designate by notice
in writing a new address to which any notice, demand, request or communication may thereafter be so given, served or sent. Each notice, demand, request, or communication which shall be delivered or transmitted in the manner described above shall be
deemed sufficiently given, served, sent and received for all purposes at such time as it is delivered to the addressee. In the case of notices sent by facsimile transmission, the notifying party shall also send a confirmation copy of any such notice
to the other party by first class-mail or registered air-mail, as appropriate. 
 8.6 Severability 
 In the event that any term of this Agreement is held to be invalid, illegal, or unenforceable, such invalidity, illegality, or unenforceability shall not affect any other portion
of this Agreement, and there shall be deemed substituted therefore such term as will most fully realize the intent of the parties as expressed in this Agreement to the fullest extent permitted by applicable law, the parties hereby declaring their
intent that this Agreement be construed in such fashion as to maintain its existence, validity, and enforceability to the greatest extent possible. 
 8.7 Survival

 Neither expiration nor termination of this Agreement shall terminate those obligations and rights of the parties pursuant to this Agreement which by their terms
are intended to survive and such provisions shall survive the expiration or termination of this Agreement. Without limiting the generality of the foregoing, the following provisions of this Agreement shall survive any expiration or termination
hereof: Sections 1, 2.2, 2.7, 2.8(b), 3.3, 3.4, 4, 5, 6, 7 and 8 and all definitional provisions of this Agreement corresponding to the foregoing. 
 8.8 Waiver

 Neither the waiver by any of the parties hereto of a breach of or a default under any of the provisions of this Agreement or any Scope of Work, nor the failure
of any of the parties, on one or more occasions, to enforce any of the provisions of this Agreement or any Scope of Work or to exercise any right or privilege hereunder or thereunder shall thereafter be construed as a waiver of any subsequent breach
or default of a similar nature, or as a waiver of any of such 
  
 ****Certain
confidential information contained in this document, marked with four asterisks, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 17 

 

 
 provisions, rights or privileges hereunder or thereunder. No waiver by a party hereto of, or consent by a party hereto to, a variation
from any provision of this Agreement or any Scope of Work shall be effective unless made in a written instrument duly executed on behalf of such party. 
 8.9
Assignment 
 This Agreement shall be binding upon and inure to the benefit of the parties hereto and their successors and assigns. While it is contemplated that
TKL may utilize approved consultants or sub-contractors in fulfillment of its obligations hereunder in accordance with Section 8.14 hereunder, TKL may not transfer or assign this Agreement (or any Scope of Work) or its obligations or rights
hereunder (or thereunder) to a third party without the prior written consent of Sponsor, and any limited utilization of consultants or sub-contractors will not relieve TKL of its obligations hereunder. To the extent that TKL does, in fact, utilize
approved consultants or sub-contractors, TKL shall ensure that said third parties agree in writing to abide by the terms of this agreement, including but not limited to the Confidentiality obligations set forth in Section 4. Any purported
assignment not in conformance with this Section 8.9, shall be null, void and of no legal effect. For clarity, Sponsor may assign this Agreement in whole or in part to any corporate affiliate or in the context of a merger, acquisition or sale of
substantially all of Sponsor’s business or assets relating to this Agreement, or by a change in control or by operation of law, in each case without the consent of the other TKL. 
 8.10 Publicity 
 TKL shall not use the name of Sponsor, its affiliates or subsidiaries (or reference any activities of Sponsor, its
affiliates or subsidiaries) in any of TKL’s promotions, public statements or other similar public disclosures without the prior express written consent of an authorized representative of Sponsor. 
 8.11 Counterparts 
 To facilitate execution, this Agreement and any Scope of Work may be
executed in as many counterparts as may be required. All counterparts shall collectively constitute a single agreement. 
 8.12 Warranties 
 It is understood that all materials and information provided hereunder are experimental in nature. Sponsor makes no warranties, express or implied, including without limitation
any of the implied warranties of merchantability, fitness for a particular purpose and non-infringement regarding any materials and/or any information provided hereunder. Additionally, Sponsor makes no representations of any kind, express or
implied, regarding the safety or efficacy with respect to such materials and/or information. 
 8.13 Non-Competition / Conflict of Interest 
 TKL agrees that it will not directly or indirectly consult or assist in the developing, testing, manufacturing, selling, importing or distributing of any product or products using
the Compound (defined below) in the Fields of Use (defined below) in the United States, Canada, Mexico, Latin America (the “Territory”), or assist or participate in, or facilitate or encourage any effort or attempt by any other person or
entity to do or seek to do any of the foregoing in the Territory. 
  
 ****Certain
confidential information contained in this document, marked with four asterisks, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 18 

 

 
 The foregoing covenants by TKL shall expire one year from the last date of submission for approval to the FDA for all indications for
which TKL is awarded a development contract as set forth in a Scope of Work. In the event that a Clinical Trial or Scope of Work is terminated by Sponsor, then the foregoing non-competition restrictions shall expire one year from the date on which
such termination occurs. Likewise, in the event a study materially fails to meet agreed- upon timeline or performance milestones for reasons beyond TKL’s control or through no fault of TKL, then the foregoing non-competition restrictions shall
expire one year from TKL’S Final Performance Milestone as Defined in this Agreement. For purposes of clarity, if either of the foregoing occurs with respect to less than the full number of indications for which TKL is awarded a development
contract as set forth in a Scope of Work, the foregoing covenants remain in full effect for all development contracts unaffected by either of the foregoing circumstances. 
 8.14 Subcontractors. 
 TKL will not subcontract or use consultants for any Services without the prior written consent of Sponsor, which consent will
not be unreasonably withheld or delayed. Sponsor will have the right to review and pre-approve contracts with any such subcontractors or consultants, and such contracts shall, at a minimum, contain terms substantially similar to those in this
Agreement with respect to compliance with law, obligations of confidentiality and non-use of Confidential Information, ownership and allocation of intellectual property rights and indemnification obligations. Any subcontractor, contractor and/or
affiliate to which TKL contemplates subcontracting Services will be named in each applicable Scope of Work. Upon consent from Sponsor, TKL will have the right to provide all or any part of the Services for a Clinical Trial through affiliates of TKL,
in which case such affiliate will execute the applicable Scope of Work and will be deemed to have executed this Agreement and agreed to be bound by the terms and conditions hereof. The phrase “Affiliates of TKL” will mean entities which
are able to provide the Services and which control, are controlled by or are under common control with TKL. Notwithstanding anything to the contrary, TKL remains responsible for the performance of any of its obligations under this Agreement that it
delegates to a subcontractor, contractor or Affiliates of TKL. 
  
 ****Certain
confidential information contained in this document, marked with four asterisks, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 19 

 

 
 IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement, or have caused this Agreement to be duly executed on
their behalf, to be effective as of the date of the last signature below (Effective Date). 
  

									
	Peplin Operations Pty Ltd	 		 	TKL Research, Inc.
					
	By:	 	/s/ Peter J. Welburn, PhD	 		 	By:	 	/s/ Robert C. Reardon, PhD
					
	Name:	 	Peter J. Welburn, PhD	 		 	Name:	 	Robert C. Reardon, PhD
					
	Title:	 	General Manager Australia, and
Chief Scientific Office	 		 	Title:	 	Executive Vice President
					
	Date:	 	2 April 2008	 		 	Date:	 	4/7/08

  
 ****Certain confidential information
contained in this document, marked with four asterisks, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 20 

 SCOPE OF WORK NO. 1 
 EXHIBIT A 
 SCOPE OF WORK 
 A multi-center, randomized, double-blind, vehicle controlled, 
 dose-ranging study to evaluate the safety and efficacy
of 0.005%, 
 0.01% and 0.015% PEP005 Topical Gel when used to treat actinic 
 keratoses on the head (face or scalp) 
 Protocol Number: PEP005-015 
 IND Number: 70,114 
 PREPARED FOR 
 Peplin Operations Pty Ltd 
 Level 2, Brisbane Portal 

 1 Breakfast Creek Road 
 Newstead

 Brisbane, Queensland 4006 
 Australia

 BY 
 TKL Research, Inc. 
 365 W. Passaic Street 
 Rochelle Park, New Jersey 07662 

March 11, 2008 
  
 ****Certain confidential information contained in this document, marked with four asterisks, has been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 21 

 Peplin
Operations Pty Ltd 
 SCOPE OF WORK NO. 1 
 EXHIBITS A-D 
 TO MASTER CLINICAL SERVICES AGREEMENT DATED 7 APRIL 2008 
 A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED DOSE-RANGING STUDY TO 
 EVALUATE THE SAFETY AND EFFICACY OF 0.005%, 0.01% AND 0.015% PEP005 TOPICAL GEL WHEN USED 
 TO TREAT ACTINIC KERATOSES ON THE HEAD (FACE OR SCALP) 

 This EXHIBIT 1-A-D TO MASTER CLINICAL SERVICES AGREEMENT (“Project Agreement”) is entered into as of March 11, 2008
(“Effective Date”), by and between Peplin Operations Pty Ltd, Level 2, Brisbane Portal, 1 Breakfast Creek Road, Newstead, Brisbane, Queensland 4006, Australia (COMPANY) and TKL Research, Inc., 365
W. Passaic Street, Rochelle Park, NJ 07662 (“TKL”). COMPANY and TKL are sometimes referred to herein individually as a “Party” and collectively as the “Parties.” 

 RECITALS: 
 WHEREAS, the
Parties entered into that certain Master Clinical Services Agreement dated 7 April 2008 (“MSA”), which outlines the rights and obligations of the Parties with respect to services provided and to be provided for
COMPANY in connection with the management and conduct of certain clinical trial projects (the “Services”) pursuant to a Project Agreement under the MSA; and 
 WHEREAS, in accordance with the MSA, the Parties wish to enter into this Project Agreement for the purpose of describing the Services to be performed in
connection with a particular study. 
 NOW, THEREFORE, in consideration of the foregoing premises, and the mutual promises and agreements
contained herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto agree as follows: 
  

	1.	DEFINITIONS: 

 Any capitalized terms not otherwise defined herein
shall have the meaning set forth in the MSA. 
  

	2.	SERVICES: 

 TKL shall perform the tasks and provide the Services
described on Scope of Work Exhibits A-D. 
  
 ****Certain confidential information
contained in this document, marked with four asterisks, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 22 

	3.	TERM: 

 The term of this Project Agreement shall commence as of
the Effective Date (the “Start Date”) and shall remain in effect until the completion of the Services, unless earlier terminated in accordance with the terms of the MSA (the “Term”). 
  

	4.	DESIGNATED EMPLOYEE FOR REPORTING PURPOSES: 

 Joseph Suttner, of
Peplin Operations USA, Inc. shall be the designated contact on behalf of Peplin Operations Pty Ltd for reporting purposes. 
  

	5.	COMPENSATION: 

 (a)        Total contract
price is **** Dollars ($****) which will be invoiced by TKL upon completion of the Services as determined by COMPANY in its reasonable discretion. Payment will be made by COMPANY within thirty (30) days following the receipt by
COMPANY of a proper invoice. All payments as described in the Payment Schedule (Exhibit 1-B) will be made via wire transfer. Wire transfer information: 
 JP Morgan Chase Bank, N.A. 
 21-10 Saddle River Road 
 Fair Lawn, NJ 07410 
 TKL Research, Inc. 
 365 W. Passaic Street 
 Rochelle Park, NJ 07662 
 Routing No./ ABA No. **** 
 Swift No. for international
transfers (****) 
 TKL Clinical Trials Division Acct. No. **** 
 (b)        The foregoing represents the total and complete price and costs to be paid to TKL by COMPANY with respect to the Services under this Project Agreement. If any additional or change in
services are to be rendered by TKL which are outside of the scope of this Project Agreement, the Parties shall follow the procedures set forth in the MSA prior to implementing any such changed or additional services. 
  

	6.	MISCELLANEOUS: 

 (a)        In addition
to the terms set forth in this Project Agreement, TKL shall also comply with all of the terms and conditions of the MSA, all of which shall govern this Project Agreement and the Services. The MSA shall remain unchanged and in full force and effect
in accordance with its original terms; provided, however, that to the extent that any of the terms and conditions of this Project Agreement are inconsistent with the terms and conditions of the MSA, the terms of this Project Agreement will govern.

 (b)        Each Party hereby represents and warrants that it has full power and authority to enter into this Project
Agreement. 
  
 ****Certain confidential information contained in this document, marked
with four asterisks, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 23 

 (a)        This Project Agreement may be executed in counterparts, each of which shall
constitute an original, and all of which, when taken together, shall constitute one and the same instrument. 
 IN WITNESS WHEREOF, each Party has caused this
Project Agreement to be executed by a duly authorized representative as of the Effective Date. 
 COMPANY: 
  

			
	PEPLIN OPERATIONS PTY LTD
		
	By:	 	/s/ Peter J. Welburn, PhD
		 	 Peter J. Welburn, PhD
 General Manager Australia and Chief Scientific Officer

 TKL: 
  

			
	TKL RESEARCH, INC.
		
	By:	 	/s/ Robert C. Reardon, PhD
		 	 Robert C. Reardon, PhD
 Executive Vice President

 Date: 4/7/08 
  
 ****Certain confidential information contained in this document, marked with four asterisks, has been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 24 

 SCOPE OF WORK NO. 1 
 EXHIBIT A 
 SCOPE OF WORK 
 ATTACHED 
  
 ****Certain confidential information contained
in this document, marked with four asterisks, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 25 

	I.	PROTOCOL SYNOPSIS 

  

	 	A.	SPONSOR 

 The SPONSOR of this project is Peplin
Operations Pty Ltd., its legally assigned successor or designee. 
  

	 	B.	TITLE/PROTOCOL #: 

 A multi-center,
randomized, double-blind, vehicle-controlled, dose-ranging study to evaluate the safety and efficacy of 0.005%, 0.01% and 0.015% PEP005 Topical Gel when used to treat actinic keratoses on the head (face or scalp) 
 Protocol No.: PEP005-015 
  

	 	C.	OBJECTIVES 

 Primary: To evaluate the safety, toleration and efficacy of 0.005%, 0.01% and 0.015% PEP005 Topical Gel compared to vehicle gel, administered as either a 2 or 3 consecutive day treatment regimen, to a 25 cm2 contiguous actinic keratosis (AK) treatment area on the face or scalp. 
 Secondary: To evaluate the efficacy of 0.005%, 0.01% and 0.015% PEP005 Topical Gel compared to vehicle gel,
administered as either a 2 or 3 consecutive day treatment regimen, to a 25 cm2 contiguous actinic keratosis (AK) treatment area on the face or scalp. 
  

	 	D.	STUDY DESIGN/DURATION 

 Study Design: 
 This is a randomized, double-blind, vehicle-controlled, dosing ranging study. Patients will be screened and randomized to one
of three PEP005 Topical Gel concentrations (0.005%, 0.01%, 0.015%) or vehicle gel for either a 2 or 3 consecutive day treatment regimen. Patients will be evaluated on the basis of safety, toleration and efficacy through 57 days following study
treatment. Treatment satisfaction and QOL will also be evaluated at various timepoints throughout the study. Post-study follow-up visits will be required for all patients with unresolved, treatment-related adverse events (AEs), local skin responses
(LSRs), pigmentation and/or scarring at Day 57. 
 Study Duration: 
 Two days study medication (Study Days 1 and 2) or three days study medication (Study Days 1, 2 and 3) 
  
 ****Certain confidential information contained in this document, marked with four asterisks, has been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 26 

	 	E.	NUMBER OF SUBJECTS AND INVESTIGATIVE SITES 

 Approximately 240 patients (30 patients per treatment group; 8 treatment groups) will be enrolled over approximately 3 months at 25 US clinical centers and
3 Australian clinical centers. 
  

	II.	SCOPE OF WORK 

  

	 	A.	TKL’s RESPONSIBILITIES 

 This proposal outlines the
proposed responsibilities and activities to be performed by TKL while acting as a consultant to SPONSOR during the conduct of this protocol. 
 All or
part of the activities identified herein will be applicable to the final study protocol and may be shared with or transferred to TKL under Title 21 CFR, Part 312.52, “Transfer of Obligations to a Contract Research Organization.”

 TKL’s Senior Project Manager will oversee both the US and the European (EU) components to ensure continuity throughout and across the study
sites. “TKL” will be used for all further references to the clinical team. TKL will be responsible for project management and US clinical monitoring. 
  

	 	1.	Protocol 

 SPONSOR will develop the protocol. TKL will obtain IRB
review of the protocol and will assist the SPONSOR in amending the protocol (one amendment if necessary). 
  

	 	2.	Project Management Team 

  

	 	•	 	 Create budget and timeline with input from Clinical Monitoring (CM), Data Management (DM), Medical Writing (MW) for review of protocol and SAE narratives and Quality
Assurance (QA). 

  

	 	•	 	 Review protocol and provide comments to SPONSOR. Design study diaries and subjects instructions as per protocol requirements. Prepare/review protocol amendments as needed.
Review draft Case Report Form (CRF) upon receipt from (DM) and compile comments from DM sponsor and project management team to achieve a final CRF. Negotiate contractual agreement with printer for the creation of CRF binders. Design source
documents. 

  

	 	•	 	 Oversee final US investigator selection, coordinate all needed Pre-Study Site Visits (PSVs) and review CRA PSVs reports. Prepare and negotiate all investigators contractual
agreements and create and a study budget grid. Prepare investigator’s regulatory packets for IRB submissions. 

  

	 	•	 	 Identify and negotiate contractual agreement with Medical Monitor. 

  

****Certain confidential information contained in this document, marked with four asterisks, has been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 27 

	 	•	 	 Interface and pay CRF printers and coordinate all deliveries to sites. 

  

	 	•	 	 Create essential site study documents (i.e., Patient Tracking Log (PTL), temperature log, study drug dispensation log, etc.) 

  

	 	•	 	 Manage all sites’ (US only) study activities such as subject enrollment, AE and protocol deviations. Communicate with SPONSOR daily/weekly as needed. Coordinate and
conduct team meetings with the SPONSOR. Track Clinical Research Associates (CRA) visit schedule and review all CRA monitoring reports. Collect documentation from Australian sites for the Trial Master File. 

  

	 	•	 	 Review invoices and authorize payments to CRF vendor only. 

  

	 	•	 	 Coordinate site closeout visits with CRAs and review reports. Track clinical supplies from sites. Review Trial Master File (TMF) for completeness and prepare for duplication
for TKL archive and ship original to SPONSOR. 

  

	 	3.	Investigator Identification and Selection 

 TKL will provide the
SPONSOR a list of potential investigators for approval. The list of potential centers to be visited for qualification will be based on TKL’s investigator’s database. All sites will be prescreened by completing a Feasibility Questionnaire,
followed by detailed, comprehensive telephone screening to determine subject database. Sites deemed acceptable will be scheduled for a Pre-Study Site Visit (PSV). Approximately 3 US sites will be qualified through PSVs as required. 
 TKL will develop subcontracts with 25 qualified US investigators to enroll and complete the study in the expected time frame. An investigator will be included
only if a subcontract acceptable to TKL is signed by the investigator. SPONSOR will review and approve proposed investigators recruited by TKL before subcontracts may be finalized between TKL and such investigators. Subcontracts with 25
investigators can be completed within two months of contact. It is estimated that each site will randomize approximately 10 subjects. 
 SPONSOR will
develop subcontracts with 3 qualified Australian sites to enroll and complete the study in the expected time frame. It is estimated that each site will randomize approximately 10 subjects. 
  

	 	4.	Pre-Study Site Qualification Visit 

 This site visit will be arranged
after the potential investigator has undergone a comprehensive telephone interview and has submitted a detailed and acceptable budget, or has indicated that the site budget will be within projected range acceptable to TKL. The objectives of the
visit will be to assess the investigator’s subject population and determine the suitability of the site to meet the needs of the protocol. A detailed site-approval checklist will be completed for review prior to final site selection. It is
anticipated that TKL will perform the pre-study site visits. However, 
  
 ****Certain
confidential information contained in this document, marked with four asterisks, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 28 

 
if SPONSOR so requests, SPONSOR may perform or accompany TKL personnel on one or more of these visits. 
  

	 	5.	Establish Investigator’s Study File 

 A file of documents critical
to study conduct will be established by TKL for the investigator to maintain at the investigational site. The purpose of this file is to document the nature, progress, and performance of the study and to facilitate the inspection by representatives
from FDA, SPONSOR and TKL. The contents of this file will be maintained by the investigator in a document binder provided to the investigator by TKL at the time of study initiation. 
  

	 	6.	Establish and Maintain Trial Master File 

 A master trial file critical
to study conduct will be established and maintained by TKL for both US and Australian sites. The purpose of this file is to document the nature, progress, monitor performance of the study and to facilitate the inspection from the FDA and SPONSOR.
The contents of this file will be maintained by TKL in a secure file cabinet from the time of study initiation. 
  

	 	7.	Regulatory Aspects 

 TKL will assist the US investigators in obtaining
IRB approval. TKL will also collect and review all necessary regulatory documentation such as FDA-1572s, CVs, and approved Subject Informed Consent Forms and assure they meet SPONSOR specifications. TKL will forward completed investigator
documentation packages, including completed clinical supply requests to SPONSOR for review and execution. 
 If an investigator fails to provide the
above described regulatory documentation, including IRB approval, within 6 weeks after acceptance of their subcontract with TKL, SPONSOR may, at its discretion, reject the investigator and require TKL to recruit a replacement acceptable to SPONSOR.

 TKL will track IRB approval dates. Additionally, TKL will distribute safety reports and safety notifications provided by SPONSOR to the
investigators and assist them with IRB submissions for these documents. 
 SPONSOR will retain the responsibility for the following regulatory
activities: i) serious adverse event reporting; and ii) reporting of additional of new investigators to the FDA. Responsibility for any of these activities may be assigned to or shared with TKL at a later date if SPONSOR determines that
internal resources will be insufficient to accomplish these tasks. 
  
 ****Certain
confidential information contained in this document, marked with four asterisks, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 29 

	 	8.	Preparation of Study Materials 

 TKL will be responsible for the
development and review of source documents, Case Report Forms (CRFs), annotated CRFs and ICF. TKL will be responsible for printing (NCR) and shipping of the CRFs. 
  

	 	9.	Clinical Study Drug 

 SPONSOR will provide packaged and labeled study
drug. TKL will be responsible for ensuring that all study drug, used and unused, is returned for disposal at the end of the clinical study. 
 TKL and
Australian monitors will check the drug records and document the date of receipt, quantity and lot numbers of all study materials shipped to the study site. Unused study materials will be inventoried, documented and returned to SPONSOR, or a
designee. The shipment date, quantity and lot numbers of returned materials will also be documented. 
 TKL will require the investigator to maintain
an accurate and up-to-date dispensation record which will be checked at each visit. That record will include the date and the amount of study medication dispensed to the subject, the amount used, and the date and quantity of study drug returned by
the subject, as well as the signatures of the dispenser and collector. 
  

	 	10.	Clinical Third Party Vendors 

  

	 	a.	Central Laboratory 

 SPONSOR will select and contract with a central
laboratory for all clinical safety labs required by the protocol and TKL will manage all aspects from the site and laboratory perspective. 
  

	 	b.	Photographic Medical Imaging 

 SPONSOR will select and contract with a
medical imaging laboratory to document and store all medical images. TKL will be responsible for managing all aspects from the site and laboratory perspective. 
  

	 	c.	IVRS for Randomization 

 SPONSOR will select and contract with an IVRS
company to randomize all patients. TKL will be responsible for managing all aspects from the site and the IVRS perspective. 
  

	 	11.	Investigator Meeting 

 SPONSOR will plan and coordinate an investigator
meeting to be attended by the investigators and assistants from each study site as well as representatives from TKL. 
  
 ****Certain confidential information contained in this document, marked with four asterisks, has been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 30 

 
The meeting will be presented jointly by SPONSOR’s and TKL at a location and date to be determined. 
 The objective of this meeting will be to orient the investigators to the requirements of the protocol with specific attention devoted to subject selection and
qualification, randomization scheme, efficacy measurement devices, interview procedures, and investigator assessments of subject progress so as to standardize methodologies across investigative sites. Case Report Forms will be reviewed with detailed
discussions of the correct procedures for completing them. The obligations of the investigators conducting investigational drug studies will be presented. All investigators who do not attend the investigator’s meeting will be initiated by a TKL
CRA. Initiations will occur after the site has a fully executed contract, IRB approval, and all study materials, clinical supplies and study drug have been delivered to the site. It is estimated that TKL will conduct 5 sites initiations. 

 

	 	12.	Clinical Monitoring 

 Site Initiation, Training and Clinical
Monitoring 
 –        Study Initiation Site Visit 
 All Clinical Research Associates (CRAs) will conduct training sessions for the investigator and assistants at each study site. The procedures for implementing the
protocol will be discussed, including: a review of the protocol objectives, assessments and timelines; source documentation requirements; and procedures for completing and submitting CRFs. The obligations of the investigators in conducting
investigational drug studies will also be reviewed and clinical supplies will be inventoried at this visit. It is estimated that TKL will conduct 5 sites initiations. 
 –        Interim Study Site Visits 
 The first interim site visit will be
scheduled after the first 1 or 2 subjects have been enrolled into the study. This close monitoring schedule will assure that the site is conducting the study as described in the protocol and determine if there are any significant problems at the
site. 
 TKL will re-visit each site approximately every 6 weeks. The monitor will review and send completed CRFs to TKL for interim analyses. Each
monitor visit will also determine that the investigator is fulfilling his obligations as outlined in the protocol, to review CRFs completed by the investigator and to ensure that the facilities being used continue to be acceptable. 
 While on-site, the CRA will review 100% of all source documents and CRFs to assure they will be complete, legible and accurate and to verify the following:

  

	 	•	 	 each subject has given informed consent to participate in the study as indicated by a duly signed consent form for each subject enrolled; 

  
 ****Certain confidential information contained in this document, marked with four asterisks, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 31 

	 	•	 	 each subject is qualified to participate in the study and conforms to the entrance and exclusion criteria set forth in the protocol; 

  

	 	•	 	 entrance and exclusion forms will be signed and dated by the investigator; 

  

	 	•	 	 subject medical histories and past medication records in the investigator’s files will be consistent with entries in the CRFs; 

  

	 	•	 	 physical examination records will be consistent with medical histories; 

  

	 	•	 	 concomitant medication or other therapy administered to the subject is permitted by the protocol; 

  

	 	•	 	 visit intervals, dosing schedules, assessments and tests were performed according to protocol guidelines and at the prescribed times; 

  

	 	•	 	 concordance exists among reports of intercurrent illness, subject complaints (AEs), physical examinations, and concomitant medications; 

  

	 	•	 	 primary subject records (i.e., charts, office files, subject dosing diaries) will be compared to CRFs to assure the accuracy and legitimacy of the data. A 100% source
document verification shall be performed; 

  

	 	•	 	 data queries will be resolved, that each resolution is properly documented, and that documentation of all resolutions is available with the subjects’ records;

  

	 	•	 	 premature termination forms have been properly completed permitting correct subject accountability. 

 The adequacy of the site will be reviewed to assure that: 
  

	 	•	 	 the site is in compliance with the institution’s IRB and federal guidelines; 

  

	 	•	 	 clinical supplies continue to be accurately accounted for and stored correctly; 

  

	 	•	 	 personnel participating in the study will be correctly documented and certification, if required, is current; 

  

	 	•	 	 documentation related to the conduct of the study is complete and current including all communication among the investigator, the IRB, SPONSOR, and TKL;

  

	 	•	 	 subject recruitment and enrollment is proceeding at a reasonable rate; 

  

	 	•	 	 CRFs will be being completed correctly and in a timely manner. 

  
 ****Certain confidential information contained in this document, marked with four asterisks, has been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 32 

 Monitored CRFs will be transmitted directly to the data processing center at TKL, all CRFs will be logged in upon
receipt and tracked through the data management process. 
 –        Close-out Study Site Visit

 A close-out site visit will be performed at each site after datalock. All remaining clinical supplies will be inventoried and returned to SPONSOR or
its designee, the investigator’s files will be reviewed to assure that all records related to the conduct of the study will be included. The CRA will verify that the investigator’s IRB was notified that the investigation concluded and that
a copy of that notification was forwarded to TKL. 
 –        Monitoring Reports 
 TKL will prepare written reports documenting each on-site monitoring visit using standard TKL monitoring forms. Additionally, status reports concerning enrollment
status and site visit activity for each site will be sent to SPONSOR weekly. The reports will include a list of any subjects discontinued from the study during the previous week, along with reasons for discontinuation. 
 –        Monitoring and Reporting Adverse Drug Reactions 
 TKL will provide a Medical Monitor for both US and Australian sites. The medical monitoring of trial will begin one month prior to the first day of enrollment and
will commence one month after last-subject/last-visit. The definition for Serious Adverse Events which must be reported within 24 hours and the form to be used for the reporting of this information to the Medical Monitor/SPONSOR will be described in
the protocol. 
 The principal investigator/sub-investigator will be instructed to report all serious adverse events (including life-threatening
adverse events or death) to TKL Project Management during business hours and to the Medical Monitor after business hours by telephone or facsimile within 24 hours of discovery. TKL will obtain follow-up information regarding such events. TKL will
forward any information compiled on each SAE to SPONSOR. 
 SPONSOR will be responsible for the determination of which events reported by the
investigators warrant FDA notification and for the preparation and filing of the summary to FDA. TKL will distribute any such reports to the investigators and assist them with the IRB notification. 
  

	 	13.	Staff 

 TKL represents and warrants that it has the facilities,
professional, technical, and clerical staff, experience, and expertise sufficient in quality and quantity to assure a 
  
 ****Certain confidential information contained in this document, marked with four asterisks, has been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 33 

 
successful and timely completion of the monitoring, data management, statistical, and writing activities. 
 TKL will designate one contact person, the Project Manager, to serve as the coordinator and primary contact between SPONSOR and TKL for the duration of the
activity. 
 TKL will use all reasonable effort to ensure the continuity of personnel assigned to the project. If a change in staff occurs, that change
will be discussed in advance with SPONSOR. 
 TKL represents and warrants that it will not permit any individual who has been disqualified and/or
debarred under Section 306 of the Federal Food, Drug and Cosmetic Act (as amended by the Generic Drug Enforcement Act of 1992), 21 U.S.C. 336, to perform any Services, or any portion thereof, pursuant to this Agreement. 
  

	 	14.	SOPs and Operational Guidelines 

 Any Standard Operating Procedures
(SOPs) and study guidelines to be followed by TKL during the course of this project will be made available by SPONSOR prior to activity initiation. In the absence of SPONSOR SOPs, TKL SOPs will be followed. Additional SOPs and guidelines may be
adopted at a later date as agreed upon by both SPONSOR and TKL to accommodate changes in the protocol, FDA requirements, and/or corporate policy of either TKL or SPONSOR. 
  

	 	15.	Discontinuation and Replacement of Investigators 

 The Sponsor shall
have the right to discontinue an investigator who is unable to enroll subjects who satisfy the Protocol inclusion and exclusion criteria according to the projection of full enrollment at approximately 1 month, defined by the date investigator
receives drug supplies and CRF books. SPONSOR shall have the right to discontinue an investigator who does not comply with the Protocol. If an investigator is discontinued, TKL will be responsible for recruiting a replacement acceptable to the
SPONSOR. 
  

	 	16.	Data Management 

 TKL will be responsible for data management, which
will include four (4) interim data transfers. TKL study monitors will interact with the data management for the resolution of queries and adverse events. 
 Data Management 
 TKL will assign a qualified lead Clinical Data Coordinator or Clinical Data Manager (CDM) to the study
project. The lead CDM will be responsible for design, preparation, and delivery of a complete database accurately reflecting the data collected in the study, in accordance with Good Clinical Practices and all regulations 
  
 ****Certain confidential information contained in this document, marked with four asterisks, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 34 

 
and conventions governing electronic data supporting applications to regulatory agencies (e.g., 21 CFR Part 11). 
 The CDM will collaborate with the study sponsor and other appropriate members of the project team to design and prepare a Case Report Form (CRF) for the collection
of clinical data as required by the study protocol and the investigational site. The CDM will also collaborate with other parties, such as external laboratories, assigned to collect data for the clinical study, to transmit these data in electronic
formats. The CDM will document the receipt and disposition of all CRF data and other study data, and will store these data in a secure manner. Paper data sources will be stored in a controlled access area protected from fire or water damage.
Electronic data sources will be stored on the TKL computer network, protected by appropriate user access controls, daily backups, and disaster recovery procedures. At the end of the study, or at pre-determined interim time points during the study,
the CDM will transfer the database along with all source documents and materials as requested to the sponsor and/or archive the materials in a secure manner for a minimum of 5 years. 
 The CDM will prepare a design specification document for the clinical study database, a Data Management Plan, which will include a description of the final
database, with data set or table names, variable or field names and formats (domain data set definitions); an annotated CRF showing the correspondence of all CRF data items with their locations in the database; guidelines for CDM review of the
source data before data entry; guidelines and conventions used in data entry; a description of formats of electronic data sources; identification of coding formats and dictionaries to be applied; and specification of edit checks to be applied by
computer program or visually in quality review of the database. 
 The CDM will design a study-specific computer application using a validated Data
Management system to permit double-key data entry and subsequent review and modification of the data by authorized staff only. The Data Management system will ensure that data entry and all changes to the data will be automatically registered in an
electronic audit trail, showing the date, time, author, and reason for the change. The audit trail will be available for review at any time. TKL Data Management staff will enter and review the data and ensure the accuracy of the data through
prescribed quality control checks. 
 The CDM will design and execute a set of quality control checks and reviews on an ongoing basis during the
process of database compilation. These checks will be designed specifically for the study to ensure that the data will be complete, within expected ranges, and self-consistent. As necessary, the CDM will issue queries to the clinical sites in order
to reconcile discrepancies in the data. The CDM will maintain an account of all such queries issued and resolved, and update the database accordingly. 
  
 ****Certain confidential information contained in this document, marked with four asterisks, has been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 35 

 Qualified Data Management staff will assign preferred term codes from standard dictionaries as required by the
protocol. Preferred term assignments will be reviewed by TKL clinical staff familiar with the medical terminology. 
 The CDM will track and report the
status of the clinical database, providing regular updated statements of the number of CRFs received, entered, and verified. The CDM will also be responsible for providing listings of data for status and quality reviews as required. 
 When all study data have been entered and verified, and all queries have been resolved, the TKL Quality Assurance (QA) department will perform a systematic audit
of the database compared to the data sources and the Data Management Plan to verify their correspondence and agreement. When all verification and QA activities have been completed, the database will be “locked” to prevent further
modifications, following approvals of the sponsor and other members of the project team as appropriate. 
 The CDM or database programmer will deliver
the final database in a format to be determined together with the sponsor, to the statistician for analysis and/or to the sponsor for distribution and archival. 
 Data Management at TKL is performed in accordance with SOPs which will be available for sponsor review on the premises of TKL. 
 Biostatistics 
 Sponsor will be responsible for the Biostatistical aspects of this trial. 
 Medical Writing 
 TKL will assign a lead medical writer
to write all SAE narratives that occur during the study. 
  

	 	B.	THE PEPLIN, INC. (SPONSOR) RESPONSIBILITIES 

  

	 	1.	SPONSOR will identify one individual to serve as primary contact for this project. 

  

	 	2.	SPONSOR will provide packaged and blinded study drug. 

  

	 	3.	TKL will permit SPONSOR’s representatives to examine the records and facilities of TKL visited study sites, and monitor the work performed hereunder, at reasonable times mutually agreed
upon by the parties and in a reasonable manner, to determine whether TKL’s performance is in compliance with the Protocol, guidelines, and relevant FDA regulations. Although SPONSOR will possess the right to do so, it will not be obligated to
do so. 

  

	 	4.	SPONSOR will provide the Investigator’s Brochure and final protocol. 

  
 ****Certain confidential information contained in this document, marked with four asterisks, has been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 36 

	III.	PROPOSAL SUMMARY 

  

	 	A.	PROPOSAL ASSUMPTIONS 

 Assumptions related
to this proposal development will be based on a study protocol dated February 19, 2008. The assumptions presented below will be subject to revision should the scope of the project or the requirements of SPONSOR change. 
  

							
		 	 1.      Number of centers:
	 	25 US sites and 3 Australian sites	 	
				
		 	 2.      Number of subjects:
	 	240	 	
				
		 	 3.      Subject participation required:
	 	57 Days	 	
				
		 	 4.      Subject enrollment period:
	 	3 Months	 	
		
		 	 5.      TKL will assist sites to obtain IRB approval of the protocol and consent form. A central IRB will be
used for any site that does not require approval from a local IRB. Assume that institutional sites must use internal IRB.

		
		 	 6.      TKL to be responsible for administration of investigator contracts and payments.

		
		 	 7.      SPONSOR will supply packaged and labeled study drug.

  

	 	B.	PROPOSED MONITORING SCHEDULE 

  

	 	1.	Approximately 158 site visits will be required to monitor this protocol in the U.S. 

  

	 	a.	We estimate 3 US Pre-Study Site Visits (PSVs). Each PSV will take 1/2 monitoring day. 

  

	 	b.	We estimate 5 Site Initiation Visits (SIVs). Each SIV will take 1 monitoring day. 

  

	 	c.	We estimate 125 Interim Monitoring visits (IMs), 5 IMVs per site. Each IM visits will take 1 monitoring day. 

  

	 	e.	We estimate 25 Close-Out Visits (COVs). Each COV will take 1 monitoring day. 

 * The Sponsor will be responsible for Monitoring the sites located in Australia 
  

	 	C.	INVESTIGATOR GRANTS 

 Investigator
contracts and grants will be directly administered through TKL for US sites only. Investigators will be required to submit a written estimated budget worksheet prior to final site selection. Payment for screen failures will be based on activities
performed to the point where a subject was excluded. Investigators with excessive screen failures may be discontinued by SPONSOR. The Sponsor will be responsible for payment to the Australian Investigators. 
  
 ****Certain confidential information contained in this document, marked with four asterisks, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 37 

	 	D.	IRB REVIEW 

 TKL will assist SPONSOR with obtaining IRB
approval of the protocol and consent form. Where acceptable and appropriate, a centralized IRB will be utilized for review. Costs for IRB review will be passed through to SPONSOR. 
  

	IV.	COSTS 

 Time and cost estimations contained in this proposal represent
TKL’s best effort to define the responsibilities and activities based on forecasts that can be rendered from current information. TKL will be conducting in-depth interview with pre-selected Investigators in order to determine recruitability of
this study. Budgets and terms of payments will be provided in the Contract Exhibit. 
  

	V.	PAYMENT SCHEDULE 

 The payment schedule for this project will be based
on the agreed schedule provided in the MSA 
 Obligations 
 TKL represents and warrants that it will perform its obligations and responsibilities hereunder in keeping with all federal, state, and local laws and regulations and with all policies and procedures of the FDA. 
 In the event of any material error or failure by TKL to perform the services described under the proposed agreement, TKL shall, at SPONSOR’s election, repeat
the services described under the proposed agreement at TKL’s own expense or repay to SPONSOR the fees associated with the particular service(s). TKL shall not, under any circumstances, be liable for incidental or consequential damages
attributable to any such error or failure to perform. It is the purpose and intent of the proposed agreement that SPONSOR shall evaluate the data submitted by TKL and shall make and be solely responsible for the decisions and policies made or to be
made on the basis of these data. 
 Independent Contractor 
 The executed Agreement shall not be construed as creating any employment or agency relationship between SPONSOR and TKL. It is understood that TKL will be acting as an independent contractor. 
  
 ****Certain confidential information contained in this document, marked with four asterisks, has
been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 38 

 SCOPE OF WORK NO. 1 
 EXHIBIT 1-B 
 BUDGET SUMMARY AND PAYMENT SCHEDULE 
 The total budget for this project is $****. Payments are to be made as follows: 
 TKL Direct Costs: 
  

	 	•	 	 Internal Costs: ($****) 

  

							
		 	****% Upon signing of the Exhibit	  	$****	  	
		 	****% First patient screened	  	$****	  	
		 	****% Upon 50% of enrollment	  	$****	  	
		 	****% Upon full enrollment	  	$****	  	
		 	****% Upon last subject off-study	  	$****	  	
		 	****% Upon database lock	  	$****	  	
		 	****% Upon TMF transfer	  	$****	  	

 Pass-Through Costs: 
  

	 	•	 	 Payment for Site Costs ($****) will be made based on meeting milestone objectives. All invoices will be paid within 30 days of invoicing as follows:

  

							
		 	****% Upon IRB approval	  	$****	  	
		 	****% Upon first patient enrolled	  	$****	  	
		 	****% Upon 50% of enrollment	  	$****	  	
		 	****% Upon 100% of (or final) enrollment	  	$****	  	
		 	****% At last patient completed	  	$****	  	
		 	****% Upon site closeout	  	$****	  	

 At the completion of the study, all Site Costs paid based on milestones will require a final accounting and must be supported
by back up documentation. TKL agrees that if on the basis of a final accounting the Sponsor has overpaid that TKL will refund the overpayment within 30 days of final accounting. 
  

	 	•	 	 All pass-through expenses ($****) will be billed on a monthly basis accompanied by back-up documentation. TKL invoices are payable upon receipt of the invoice.

  
 ****Certain confidential information contained in this document,
marked with four asterisks, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 39 

 SCOPE OF WORK NO. 1 
 EXHIBIT B 
 SUMMARY BUDGET PROPOSAL 
 ATTACHED 
  
 ****Certain confidential
information contained in this document, marked with four asterisks, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 40 

 SCOPE OF WORK NO. 1 
  
 ****Certain confidential information contained in this document, marked with four asterisks, has been omitted and filed separately with the
Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 41 

 EXHIBIT B 
 Summary Budget Proposal 
 Phase II Actinic Keratoses on the head, (face or scalp) 
 PEP005-015
 March 11, 2008 
  

					
	Assumptions:	 	25	 	U.S. sites, 3 Australian sites
		 	240	 	subjects
		 	3	 	month enrollment
		 	2	 	month treatment

  

					
	Internal Costs	  	  	  	Cost
			
	 Project/Site Management
	  	(13 months )	  	                    $****
			
	 Monitoring (U.S. Only)
	  	( 3 PSV, 5 SIV, 125 1-DIM, 25 COV )	  	$****
			
	 Recruitment Management
	  	( U.S. Only - PEP Related )	  	$****
			
	 Data Management
	  		  	$****
			
	 Biostatistics
	  		  	$****
			
	 Medical Writing
	  	( Protocol Review Only )	  	$****
			
	 SAE Narratives
	  		  	$****
			
	 Quality Assurance
	  		  	$****
			
	 Pharmcovigilance
	  		  	$****
			
	 Document Archiving Fee
	  		  	$****
		  		  	 
			
		  	Sub-Total	  	$****
		  		  	 
			
	 Pass-Through Expenses
	  	 	  	 
			
	 Advertising ( U.S. Only )
	  		  	$****
			
	 Advertising Expenses ( PEP Related )
	  		  	$****
			
	 IRB ( U.S. Only )
	  		  	$****
			
	 CRF Printing
	  		  	$****
			
	 Investigator Meeting
	  	15 attendees - $****/person	  	$****
			
	 Site Costs*
	  	( U.S. Sites Only )	  	$****
			
	 Photography
	  		  	$****
			
	 Monitoring Travel
	  		  	$****
			
	 Miscellaneous (supplies, translations, international calls etc.)
	  		  	$****
			
	 Shipping
	  		  	$****
		  		  	 
			
		  	Subt-Total	  	$****
		  		  	 
			
		  	Grand Total	  	$****

					
	• Assumes:	 	$****/site preparation fee	    	$****/screen failure (maximum 5/site)
		 	$****/completed patient	    	

  
 ****Certain confidential information
contained in this document, marked with four asterisks, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 42 

 SCOPE OF WORK NO. 1 
 EXHIBIT C 
 DRAFT STUDY TIMELINE 
  

													
	 Peplin Actinic Keratoses
 Protocol No. PEP005-015
	  	 
	 DRAFT
	  	Target Date	  	 	  	Revision
****	  	 	  	Actual Date	  	 
	 Pre-Study
	  	 	  	 	  	 	  	 	  	 	  	 
	 Protocol Finalized
	  	****	  	 	  	 	  	 	  	****	  	 
	 Case Report Forms
	  	 	  	 	  	 	  	 	  	 	  	 
	 Draft CRFs
	  	****	  	 	  	****	  	 	  	 	  	 
	 Sponsor Comments Returned
	  	****	  	 	  	****	  	 	  	 	  	 
	 CRFs final (Post IM)
	  	****	  	 	  	****	  	 	  	 	  	 
	 CRF Sent for Printing
	  	****	  	 	  	****	  	 	  	 	  	 
	 Delivery to sites (**** to ****)
	  	****	  	 	  	****	  	 	  	 	  	 
	 Draft Source Documents
	  	****	  	 	  	****	  	 	  	 	  	 
	 Final Source Documents
	  	****	  	 	  	****	  	 	  	 	  	 
	 Initiation / Enrollment
	  	 	  	 	  	 	  	 	  	 	  	 
	 Preliminary Site Selection Finalized
	  	****	  	 	  	 	  	 	  	****	  	 
	 Site/TKL Contracts finalized
	  	****	  	 	  	 	  	 	  	 	  	 
	 Regulatory Packages Sent to Sites
(rolling)
	  	(first) ****	  	 	  	 	  	 	  	****	  	 
	 Return Site Regulatory Documents to TKL
(rolling)
	  	(last) ****	  	 	  	 	  	 	  	 	  	 
	 Investigator’s Meeting
	  	****-****	  	 	  	 	  	 	  	 	  	 
	 Vendors
	  	 	  	 	  	 	  	 	  	 	  	 
	 IVRS Testing
	  	****	  	 	  	 	  	 	  	 	  	 
	 Covance Supply Arrival Date
	  	 	  	 	  	 	  	 	  	 	  	 
	 Canfield Camera shipment to Sites
	  	****	  	 	  	 	  	 	  	 	  	 
	 Central IRB Process
	  	 	  	 	  	 	  	 	  	 	  	 
	 a)  Initial IRB Submission (Quorum)
	  	****	  	 	  	 	  	 	  	****	  	 
	 b)  Project Approval
	  	****	  	 	  	 	  	 	  	 	  	 
	 c)  Final Site Submission (Australia
****)
	  	****	  	 	  	 	  	 	  	 	  	 
	 d)  Final Site Approval (Australia
****)
	  	****	  	 	  	 	  	 	  	 	  	 
	 IRB Project & Site Approvals to
Sponsor
	  	****	  	 	  	 	  	 	  	 	  	 
	 Almac Site Activation/Drug Shipment to Sites
	  	****	  	 	  	 	  	 	  	 	  	 
	 PEP Media Flights Begin
	  	****	  	 	  	 	  	 	  	 	  	 
	 Start-up FPI
	  	****	  	 	  	 	  	 	  	 	  	 
	 Contracted FPI
	  	****	  	 	  	 	  	 	  	 	  	 
	 LPI (3 month enrollment period)
	  	****	  	 	  	****	  	 	  	 	  	 
	 LPO
	  	****	  	 	  	****	  	 	  	 	  	 
	 Site Closeouts
	  	****-****	  	 	  	 	  	 	  	 	  	 
	 Data Management Process
	  	 	  	 	  	 	  	 	  	 	  	 
	 Draft DMP
	  	****	  	 	  	 	  	 	  	 	  	 

  
 ****Certain confidential information
contained in this document, marked with four asterisks, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 43 

													
	 Final DMP
	  	****	  	 	  	 	  	 	  	 	  	 
	 First CRF In-House
	  	****	  	 	  	 	  	 	  	 	  	 
	 Data Entry Begins
	  	****	  	 	  	 	  	 	  	 	  	 
	 First Data Transfer
	  	****	  	 	  	 	  	 	  	 	  	 
	 Second Data Transfer
	  	****	  	 	  	 	  	 	  	 	  	 
	 Last CRF In-house
	  	****	  	 	  	****	  	 	  	 	  	 
	 Third Data Transfer
	  	****	  	 	  	 	  	 	  	 	  	 
	 Data Entry Complete
	  	****	  	 	  	****	  	 	  	 	  	 
	 Data Listings to QA
	  	****	  	 	  	 	  	 	  	 	  	 
	 Blinded Data Review Meeting
	  	****	  	 	  	 	  	 	  	 	  	 
	 QA Review Complete
	  	****	  	 	  	 	  	 	  	 	  	 
	 Database Lock
	  	****	  	 	  	****	  	 	  	 	  	 
	 Final Data Transfer
	  	****	  	 	  	****	  	 	  	 	  	 

  
 ****Certain confidential information
contained in this document, marked with four asterisks, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 44 

 

 
 SCOPE OF WORK NO. 1 
 EXHIBIT D 
 CANCELLATION FEES 
 AND 
 PROJECT MANAGEMENT ALLOCATION 
  

																											
	 	 	PreStudy	 	Enrollment	 	Treatment	 	Close Out
	AK	 	Mo. 1	 	Mo. 2	 	Mo. 3	 	Mo. 4	 	Mo. 5	 	Mo. 6	 	Mo. 7	 	Mo. 8	 	Mo. 9	 	Mo. 10	 	Mo. 11	 	Mo. 12	 	Mo. 13
	 Project Management
	 	$****	 	$****	 	$****	 	$****	 	$****	 	$****	 	$****	 	$****	 	$****	 	$****	 	$****	 	$****	 	$****
	 Clinical Monitoring
	 	$****	 	$****	 	$****	 	$****	 	$****	 	$****	 	$****	 	$****	 	$****	 	$****	 	$****	 	$****	 	$****
	 TOTAL MONTHLY CHARGE
	 	$****	 	$****	 	$****	 	$****	 	$****	 	$****	 	$****	 	$****	 	$****	 	$****	 	$****	 	$****	 	 $****

  
 ****Certain confidential information
contained in this document, marked with four asterisks, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 45

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00147-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00147-of-00352.parquet"}]]